Trosolwyg
I have worked in the complement system for over thirty years, leading a research group working on basic complement biology and relevance of complement to human disease. I have had a long-standing interest in the membrane attack complex (MAC), its effects on nucleated cells and how nucleated cells respond to MAC attack; this work has led to several seminal discoveries, including the process of nucleated cell recovery from membrane attack and the mechanism by which CD59 regulates MAC formation. More recently, I have demonstrated that the MAC triggers inflammasome activation in diverse cells and contributed to new understanding of MAC structure, using this knowledge to predict function.
Cyhoeddiad
2025
- Zelek, W. M., Bevan, R. J., Nimo, J. M., Dewilde, M., De Strooper, B. and Morgan, B. P. 2025. Targeting novel anti‐complement drugs to the brain reduces complement activation and synapse loss, and improves cognition in a mouse model of dementia. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 20(S6) (10.1002/alz.090708)
2024
- Zelek, W. M., Bevan, R. J., Nimmo, J., Dewilde, M., De Strooper, B. and Morgan, B. P. 2024. Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model. Brain (10.1093/brain/awae278)
- Zelek, W. M., Bevan, R. J. and Morgan, B. P. 2024. Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia. Brain, Behavior, and Immunity 118, pp. 355-363. (10.1016/j.bbi.2024.03.017)
- Baillie, K. et al. 2024. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. Med 5(3), pp. 239-253. (10.1016/j.medj.2024.01.011)
- Daskoulidou, N., Carpanini, S., Zelek, W. and Morgan, B. P. 2024. Involvement of complement in Alzheimer's Disease: From genetics through pathology to therapeutic strategies. In: Ellenbroek, B. A. et al. eds. Current Topics in Behavioral Neurosciences. Springer, Berlin, Heidelberg, pp. 1-22., (10.1007/7854_2024_524)
2023
- Kamegai, N. et al. 2023. Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model. Clinical & Experimental Immunology 214(2), pp. 209-218. (10.1093/cei/uxad088)
- Karbian, N. et al. 2023. Complement-membrane regulatory proteins are absent from the nodes of Ranvier in the peripheral nervous system. Journal of Neuroinflammation 20(1), article number: 245. (10.1186/s12974-023-02920-9)
- Daskoulidou, N. et al. 2023. Complement receptor 1 is expressed on brain cells and in the human brain. Glia 71(6), pp. 1522-1535. (10.1002/glia.24355)
- Veteleanu, A. et al. 2023. Complement dysregulation and Alzheimer's disease in Down syndrome. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 19(4), pp. 1383-1392. (10.1002/alz.12799)
- Siggins, M. K. et al. 2023. Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.. Immunology 168(3), pp. 473-492. (10.1111/imm.13585)
- Stevenson-Hoare, J. et al. 2023. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease. Brain 146(2), pp. 690-699. (10.1093/brain/awac128)
2022
- Lekova, E. et al. 2022. Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. Frontiers in Immunology 13, article number: 968206. (10.3389/fimmu.2022.968206)
- Zelek, W. M. and Morgan, B. P. 2022. Targeting complement in neurodegeneration: challenges, risks, and strategies. Trends in Pharmacological Sciences 43(8), pp. 615-628. (10.1016/j.tips.2022.02.006)
- Carpanini, S. M. et al. 2022. Terminal complement pathway activation drives synaptic Loss in Alzheimer’s disease models. Acta Neuropathologica Communications 10, article number: 99. (10.1186/s40478-022-01404-w)
- Banda, N. K. et al. 2022. Analysis of complement gene expression, clinical associations, and biodistribution of complement proteins in the synovium of early rheumatoid arthritis patients reveals unique pathophysiologic features. Journal of Immunology 208(11), pp. 2482-2496. (10.4049/jimmunol.2101170)
- Fielding, C. A. et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11 (10.7554/eLife.74489)
- Lewis, L. A. et al. 2022. Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement. The Journal of Infectious Diseases 225(10), pp. 1861–1864. (10.1093/infdis/jiab630)
- Gytz Olesen, H. et al. 2022. Development, characterization, and in vivo validation of a humanized C6 monoclonal antibody that Inhibits the membrane attack complex. Journal of Innate Immunity (10.1159/000524587)
- Kolka, C. M. et al. 2022. C5b-9 membrane attack complex formation and extracellular vesicle shedding in Barrett's esophagus and esophageal adenocarcinoma. Frontiers in Immunology 13, article number: 842023. (10.3389/fimmu.2022.842023)
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165(2), pp. 250-259. (10.1111/imm.13433)
- Cooze, B. et al. 2022. The association between neurodegeneration and local complement activation in the thalamus to progressive multiple sclerosis outcome.. Brain Pathology 32, article number: e13054. (10.1111/bpa.13054)
- Westacott, L. J. et al. 2022. Complement C3 and C3aR mediate different aspects of emotional behaviours; relevance to risk for psychiatric disorder. Brain, Behavior, and Immunity 99, pp. 70-82. (10.1016/j.bbi.2021.09.005)
2021
- Torvell, M., Carpanini, S. M., Daskoulidou, N., Byrne, R. A. J., Sims, R. and Morgan, B. P. 2021. Genetic insights into the impact of complement in Alzheimer's disease. Genes 12(12), article number: 1990. (10.3390/genes12121990)
- Chakraborty, M. et al. 2021. nSeP: immune and metabolic biomarkers for early detection of neonatal sepsis-protocol for a prospective multicohort study. BMJ Open 11(12), article number: e050100. (10.1136/bmjopen-2021-050100)
- Westacott, L. J. et al. 2021. Dissociable effects of complement C3 and C3aR on survival and morphology of adult born hippocampal neurons, pattern separation, and cognitive flexibility in male mice. Brain, Behavior, and Immunity 98, pp. 136-150. (10.1016/j.bbi.2021.08.215)
- Wong, E. et al. 2021. C3 Glomerulopathy and related disorders in children. Clinical Journal of the American Society of Nephrology 16(11), pp. 1639-1651. (10.2215/CJN.00320121)
- Byrne, R. A. J., Torvell, M., Daskoulidou, N., Fathalla, D., Kokkali, E., Carpanini, S. M. and Morgan, B. P. 2021. Novel monoclonal antibodies against mouse C1q: characterisation and development of a quantitative ELISA for mouse C1q. Molecular Neurobiology 58(9), pp. 4323-4336. (10.1007/s12035-021-02419-5)
- MacKenzie, G. et al. 2021. Research priorities for neuroimmunology: identifying the key research questions to be addressed by 2030. Wellcome Open Research 6, article number: 194. (10.12688/wellcomeopenres.16997.1)
- Mc Mahon, O. et al. 2021. The rare C9 P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade. Human Molecular Genetics 30(13), pp. 1188-1199. (10.1093/hmg/ddab086)
- Webster, J. A. et al. 2021. Development of EndoScreen chip, a microfluidic pre-endoscopy triage test for esophageal adenocarcinoma. Cancers 13(12), article number: 2865. (10.3390/cancers13122865)
- Carpanini, S. M., Harwood, J. C., Baker, E., Torvell, M., Sims, R., Williams, J. and Morgan, B. P. 2021. The impact of complement genes on the risk of late-onset Alzheimer's disease. Genes 12(3), article number: 443. (10.3390/genes12030443)
- Morgan, B. P., Gommerman, J. L. and Ramaglia, V. 2021. An “outside-in” and “inside-out” consideration of complement in the multiple sclerosis brain: lessons from development and neurodegenerative diseases. Frontiers in Cellular Neuroscience 14, article number: 600656. (10.3389/fncel.2020.600656)
- Murrell, I. et al. 2021. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. PLoS ONE 16(1), article number: e0245382. (10.1371/journal.pone.0245382)
- Rodrigues, P. R., Picco, N., Morgan, B. P. and Ghazal, P. 2021. Sepsis target validation for repurposing and combining complement and immune checkpoint inhibition therapeutics. Expert Opinion on Drug Discovery 16(5), pp. 537-551. (10.1080/17460441.2021.1851186)
2020
- Buckland, M. S. et al. 2020. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nature Communications 11(1), article number: 6385. (10.1038/s41467-020-19761-2)
- Zelek, W. M. and Morgan, B. P. 2020. Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species. Frontiers in Immunology 11(11), article number: 612402. (10.3389/fimmu.2020.612402)
- Bevan, R. J., Hughes, T. R., Williams, P. A., Good, M. A., Morgan, B. P. and Morgan, J. E. 2020. Retinal ganglion cell degeneration correlates with hippocampal spine loss in experimental Alzheimer's disease. Acta Neuropathologica Communications 8(1), article number: 216. (10.1186/s40478-020-01094-2)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26(14), pp. 1929-1937. (10.1177/1352458519887905)
- O'Connor, D. B. et al. 2020. Research priorities for the COVID-19 pandemic and beyond: a call to action for psychological science. British Journal of Psychology 111(4), pp. 603-629., article number: e12468. (10.1111/bjop.12468)
- Zelek, W. M. et al. 2020. Complement inhibition with the C5 blocker LFG316 in severe COVID-19. American Journal of Respiratory and Critical Care Medicine 202(9), pp. 1304-1308. (10.1164/rccm.202007-2778LE)
- Zelek, W. M., Menzies, G. E., Brancale, A., Stockinger, B. and Morgan, B. P. 2020. Characterising the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. Immunology 161(2), pp. 103-113., article number: Volume161, Issue2 October 2020 Pages 103-113. (10.1111/imm.13228)
- Shi, L. et al. 2020. Dickkopf-1 overexpression in vitro nominates candidate blood biomarkers relating to Alzheimer's disease pathology. Journal of Alzheimer's Disease 77(3), pp. 1353-1368. (10.3233/JAD-200208)
- Jackson, H. M., Foley, K. E., O'Rourke, R., Stearns, T. M., Fathalla, D., Morgan, B. P. and Howell, G. R. 2020. A novel mouse model expressing human forms for complement receptors CR1 and CR2. BMC Genetics 21(1), article number: 101. (10.1186/s12863-020-00893-9)
- van Dijk, B. J. et al. 2020. Complement C5 contributes to brain injury after subarachnoid hemorrhage. Translational Stroke Research 11, pp. 678-688. (10.1007/s12975-019-00757-0)
- Mondelli, V., Di Forti, M., Morgan, B. P., Murray, R. M., Pariante, C. M. and Dazzan, P. 2020. Baseline high levels of complement component 4 predict worse clinical outcome at 1-year follow-up in first-episode psychosis. Brain, Behavior, and Immunity 88, pp. 913-915. (10.1016/j.bbi.2020.01.014)
- Altmann, T. et al. 2020. Complement factor I deficiency: a potentially treatable cause of fulminant cerebral inflammation. Neurology, Neuroimmunology and Neuroinflammation 7(3), article number: e689. (10.1212/NXI.0000000000000689)
- Ghias, M. H., Hyde, M. J., Tomalin, L. E., Morgan, B. P., Alavi, A., Lowes, M. A. and Piguet, V. 2020. Role of the complement pathway in inflammatory skin diseases: a focus on hidradenitis suppurativa. Journal of Investigative Dermatology 140(3), pp. 531-536.e1. (10.1016/j.jid.2019.09.009)
- Westwood, S. et al. 2020. Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort. Journal of Alzheimer's Disease 74(1), pp. 213-225. (10.3233/JAD-190434)
- Cipriani, V. et al. 2020. Increased circulating levels of Factor H-Related Protein 4 are strongly associated with age-related macular degeneration. Nature Communications 11, article number: 778. (10.1038/s41467-020-14499-3)
2019
- Shi, L. et al. 2019. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia 15(11), pp. 1478-1488. (10.1016/j.jalz.2019.06.4951)
- Mancuso, R. et al. 2019. CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain 142(10), pp. 3243-3264. (10.1093/brain/awz241)
- Zelek, W. M., Xie, L., Morgan, B. P. and Harris, C. L. 2019. Compendium of current complement therapeutics. Molecular Immunology 114, pp. 341-352. (10.1016/j.molimm.2019.07.030)
- Mastellos, D. C. et al. 2019. 'Stealth' corporate innovation: an emerging threat for therapeutic drug development. Nature Immunology 20(11), pp. 1409-1413. (10.1038/s41590-019-0503-1)
- Zelek, W. M., Taylor, P. R. and Morgan, B. P. 2019. Development and characterisation of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species. Immunology 157(4), pp. 283-295. (10.1111/imm.13083)
- Yang, J. et al. 2019. Complement factor C5 inhibition reduces type 2 responses without affecting group 2 innate lymphoid cells in a house dust mite induced murine asthma model. Respiratory Research 20(1), pp. -., article number: 165. (10.1186/s12931-019-1136-5)
- Baker, E. et al. 2019. Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer’s disease. PLoS ONE 14(7), article number: e0218111. (10.1371/journal.pone.0218111)
- Morgan, A. R. et al. 2019. Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's & Dementia 15(6), pp. 776-787. (10.1016/j.jalz.2019.03.007)
- Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25(4), pp. 523-531. (10.1177/1352458518758927)
- Goutaudier, V. et al. 2019. C5b9 deposition in glomerular capillaries is associated with poor kidney allograft survival in antibody-mediated rejection. Frontiers in Immunology 10, pp. -., article number: 235. (10.3389/fimmu.2019.00235)
- Carpanini, S. M., Torvell, M. and Morgan, B. P. 2019. Therapeutic inhibition of the complement system in diseases of the central nervous system. Frontiers in Immunology 10, pp. -., article number: 362. (10.3389/fimmu.2019.00362)
- Kopczynska, M. et al. 2019. Complement system biomarkers in first episode psychosis. Schizophrenia Research 204, pp. 16-22. (10.1016/j.schres.2017.12.012)
2018
- Karbian, N. et al. 2018. Molecular pathogenesis of human CD59 deficiency. Neurology Genetics 4(6), article number: e280. (10.1212/NXG.0000000000000280)
- Menny, A. et al. 2018. CryoEM reveals how the complement membrane attack complex ruptures lipid bilayers. Nature Communications 9, article number: 5316. (10.1038/s41467-018-07653-5)
- Zelek, W. M., Harris, C. L. and Morgan, B. P. 2018. Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers. Immunobiology 223(12), pp. 744-749. (10.1016/j.imbio.2018.07.016)
- Griffiths, M. R., Botto, M., Morgan, B. P., Neal, J. W. and Gasque, P. 2018. CD93 regulates central nervous system inflammation in two mouse models of autoimmune encephalomyelitis. Immunology 155(3), pp. 346-355. (10.1111/imm.12974)
- Zelek, W. M., Stott, M., Walters, D., Harris, C. L. and Morgan, B. P. 2018. Characterising a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. Immunology 155(3), pp. 396-403. (10.1111/imm.12982)
- Kopczynska, M. et al. 2018. Complement system biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60, pp. 1-7. (10.1016/j.seizure.2018.05.016)
- Loveless, S. et al. 2018. Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis. Brain Pathology 28(4), pp. 507-520. (10.1111/bpa.12546)
- Michailidou, I. et al. 2018. Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications 6(1), article number: 36. (10.1186/s40478-018-0536-y)
- Mihai, S. et al. 2018. Specific inhibition of complement activation significantly ameliorates autoimmune blistering disease in mice. Frontiers in Immunology 9, article number: 535. (10.3389/fimmu.2018.00535)
- Morgan, B. P. 2018. Complement in the pathogenesis of Alzheimer's disease. Seminars in Immunopathology 40(1), pp. 113-124. (10.1007/s00281-017-0662-9)
- Boshra, H., Zelek, W. M., Hughes, T. R., Rodriguez de Cordoba, S. and Morgan, B. P. 2018. Absence of CD59 in guinea pigs: Analysis of the Cavia porcellus genome suggests the evolution of a CD59 pseudogene. Journal of Immunology 200(1), pp. 327-335. (10.4049/jimmunol.1701238)
2017
- Morgan, A., O'Hagan, C., Touchard, S., Lovestone, S. and Morgan, B. P. 2017. Effects of freezer storage time on levels of complement biomarkers. BMC Research Notes 10(1), article number: 559. (10.1186/s13104-017-2885-1)
- Stott, M., van den Berg, C., Forton, J., Monk, P., Morgan, B. P. and McGreal, E. 2017. Post-translational modification of complement anaphylatoxins during chronic neutrophilic inflammation. Molecular Immunology 89, pp. 167., article number: 103. (10.1016/j.molimm.2017.06.141)
- Taylor, R. P. et al. 2017. Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9. Clinical Immunology 181, pp. 24-28. (10.1016/j.clim.2017.05.016)
- Morgan, B. P., Boyd, C. and Bubeck, D. 2017. Molecular cell biology of complement membrane attack. Seminars in Cell and Developmental Biology
- Hakobyan, S., Luppe, S., Evans, D. R. S., Harding, K., Loveless, S., Robertson, N. P. and Morgan, B. P. 2017. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal 23(7), pp. 946-955., article number: 135245851666900. (10.1177/1352458516669002)
- Granados-Durán, P. et al. 2017. Microbial neuraminidase induces a moderate and transient myelin vacuolation independent of complement system activation. Frontiers in Neurology 8, article number: 78. (10.3389/fneur.2017.00078)
- Morgan, A. et al. 2017. The correlation between inflammatory biomarkers and polygenic risk score in Alzheimer's Disease. Journal of Alzheimer's Disease 56(1), pp. 25-36. (10.3233/JAD-160889)
- Stover, C. M. et al. 2017. High levels of soluble C5b-9 complex in dialysis fluid may predict poor prognosis in peritonitis in peritoneal dialysis patients. PLoS ONE 12(1), article number: e0169111. (10.1371/journal.pone.0169111)
2016
- Granados-Duran, P. et al. 2016. Complement system activation contributes to the ependymal damage induced by microbial neuraminidase. Journal of Neuroinflammation 13(115) (10.1186/s12974-016-0576-9)
- Morgan, B. P., Walters, D., Serna, M. and Bubeck, D. 2016. Terminal complexes of the complement system: new structural insights and their relevance to function. Immunological Reviews 274(1), pp. 141-151. (10.1111/imr.12461)
- Hakobyan, S. et al. 2016. Complement biomarkers as predictors of disease progression in Alzheimer's disease. Journal of Alzheimer's Disease 54(2), pp. 707-716. (10.3233/JAD-160420)
- Heurich-Sevcenco, M., Preston, R., O'Donnell, V. B., Morgan, B. P. and Collins, P. W. 2016. Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research 145, pp. 84-92. (10.1016/j.thromres.2016.07.017)
- Towner, L. D., Wheat, R. A., Hughes, T. R. and Morgan, B. P. 2016. Complement membrane attack and tumorigenesis: a systems biology approach. Journal of Biological Chemistry 291(29), pp. 14927-14938. (10.1074/jbc.M115.708446)
- Challis, R. C. et al. 2016. A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H/complement factor H-related 3 gene in atypical hemolytic uremic syndrome. Journal of the American Society of Nephrology 27(6), pp. 1617-1624. (10.1681/ASN.2015010100)
- Watkins, L. M. et al. 2016. Complement is activated in progressive multiple sclerosis cortical grey matter lesions. Journal of Neuroinflammation 13, article number: 161. (10.1186/s12974-016-0611-x)
- Morgan, B. P. 2016. The membrane attack complex as an inflammatory trigger. Immunobiology 221(6), pp. 747-751. (10.1016/j.imbio.2015.04.006)
- Williams, P. A. et al. 2016. Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma. Molecular Neurodegeneration 11, article number: 26. (10.1186/s13024-016-0091-6)
- Bloom, A. C. et al. 2016. Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice. Bone 84, pp. 253-261. (10.1016/j.bone.2015.12.014)
- Bahia El Idrissi, N., Hakobyan, S., Ramaglia, V., Geluk, A., Morgan, B. . P., Das, P. K. and Baas, F. 2016. Complement activation in leprosy: a retrospective study shows elevated circulating terminal complement complex in reactional leprosy. Clinical and Experimental Immunology 184(3), pp. 338. (10.1111/cei.12767)
- Moore, G. R. W., Laule, C., Leung, E., Pavlova, V., Morgan, B. P. and Esiri, M. M. 2016. Complement and humoral adaptive immunity in the human choroid plexus: roles for stromal concretions, basement membranes, and epithelium. Journal of Neuropathology and Experimental Neurology 75(5), pp. 415-428. (10.1093/jnen/nlw017)
- Szarvas, N. et al. 2016. Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Molecular Immunology 71, pp. 10-22. (10.1016/j.molimm.2016.01.003)
- Serna, M., Giles, J. L., Morgan, B. P. and Bubeck, D. 2016. Structural basis of complement membrane attack complex formation. Nature Communications 7, article number: 10587. (10.1038/ncomms10587)
- Triantafilou, M., Hughes, T., Morgan, B. and Triantafilou, K. 2016. Complementing the inflammasome. Immunology 147(2), pp. 152-164. (10.1111/imm.12556)
2015
- Ruseva, M. M., Ramaglia, V., Morgan, B. P. and Harris, C. L. 2015. An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice. Proceedings of the National Academy of Sciences 112(46), pp. 14319-14324. (10.1073/pnas.1513698112)
- Mook-Kanamori, B. B. et al. 2015. Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis. Journal of Thrombosis and Haemostatis 13(11), pp. 2076-2086. (10.1111/jth.13132)
- Morgan, B. 2015. The role of complement in neurological and neuropsychiatric diseases. Expert Review of Clinical Immunology 11(10), pp. 1109-1119. (10.1586/1744666X.2015.1074039)
- Martínez-Barricarte, R. et al. 2015. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Molecular Immunology 66(2), pp. 263-273. (10.1016/j.molimm.2015.03.248)
- Kasanmoentalib, E. S., Valls Seron, M., Morgan, B. P., Brouwer, M. C. and van de Beek, D. 2015. Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial. Journal of Neuroinflammation 12(1), article number: 149. (10.1186/s12974-015-0372-y)
- Giles, J. L., Choy, E., van den Berg, C., Morgan, B. P. and Harris, C. L. 2015. Response to comment on 'Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis'. Journal of Immunology 195(1), pp. 4-4. (10.4049/jimmunol.1500968)
- Bahia El Idrissi, N. et al. 2015. M. leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator. Acta Neuropathologica 129(5), pp. 653-667. (10.1007/s00401-015-1404-5)
- Ramaglia, V., Jackson, S. J., Hughes, T., Neal, J., Baker, D. and Morgan, B. 2015. Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Clinical & Experimental Immunology 180(3), pp. 432-441. (10.1111/cei.12595)
- Owen, E. P. et al. 2015. A complement C5 gene mutation, c.754G>A:p.A252T, is common in the Western Cape, South Africa and found to be homozygous in seven percent of Black African meningococcal disease cases. Molecular Immunology 64(1), pp. 170-176. (10.1016/j.molimm.2014.11.010)
- Giles, J., Choy, E. H. S., Van Den Berg, C., Morgan, B. P. and Harris, C. L. 2015. Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis. The Journal of Immunology 194(7), pp. 3029-3034. (10.4049/jimmunol.1402956)
2014
- Subias, M. et al. 2014. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models. The Journal of Immunology 193(11), pp. 5567-5575. (10.4049/jimmunol.1402013)
- Giles, J. L., Choy, E., van den Berg, C., Morgan, B. P. and Harris, C. L. 2014. Functional analysis of a complement polymorphism (rs17611) associated with Rheumatoid Arthritis. Immunology 143(s2), pp. 181-182. (10.1111/imm.12407)
- Clark, S. J., Schmidt, C. Q., White, A. W., Hakobyan, S., Morgan, B. and Bishop, P. N. 2014. Identification of factor H-like protein 1 as the predominant complement regulator in Bruch's membrane: implications for age-related macular degeneration. The Journal of Immunology 193(10), pp. 4962-4970. (10.4049/jimmunol.1401613)
- Paixao-Cavalcante, D. et al. 2014. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors. The Journal of Immunology 192(10), pp. 4844-4851. (10.4049/jimmunol.1303131)
- Ingram, G. et al. 2014. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathologica Communications 2, article number: 53. (10.1186/2051-5960-2-53)
- Fluiter, K., Opperhuizen, A. L., Morgan, B., Baas, F. and Ramaglia, V. 2014. Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice. The Journal of Immunology 192(5), pp. 2339-2348. (10.4049/jimmunol.1302793)
2013
- Pickering, M. C. et al. 2013. C3 glomerulopathy: consensus report. Kidney International 84(6), pp. 1079-1089. (10.1038/ki.2013.377)
- Liu, J. et al. 2013. Myeloid cells expressing VEGF and Arginase-1 following uptake of damaged retinal pigment epithelium suggests potential mechanism that drives the onset of choroidal angiogenesis in mice. PLoS ONE 8(8), article number: e72935. (10.1371/journal.pone.0072935)
- Khandhadia, S. et al. 2013. Age-related macular degeneration and modification of systemic complement factor H production through liver transplantation. Ophthalmology 120(8), pp. 1612-1618. (10.1016/j.ophtha.2013.01.004)
- Triantafilou, K., Hughes, T. R., Triantafilou, M. and Morgan, B. P. 2013. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. Journal of Cell Science 126(13), pp. 2903-2913. (10.1242/jcs.124388)
- Laudisi, F. et al. 2013. Cutting edge: The NLRP3 inflammasome links complement-mediated inflammation and IL-1β release. The Journal of Immunology 191(3), pp. 1006-1010. (10.4049/jimmunol.1300489)
- Killick, R., Hughes, T. R., Morgan, B. P. and Lovestone, S. 2013. Corrigendum to “Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH” [Neurosci. Lett. 533 (2013) 96–99] [Corrigendum]. Neuroscience Letters 545, pp. 144-144. (10.1016/j.neulet.2013.05.004)
- Goicoechea de Jorge, E. et al. 2013. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proceedings of the National Academy of Sciences of the United States of America 110(12), pp. 4685-4690. (10.1073/pnas.1219260110)
- Clark, S. J. et al. 2013. Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. The Journal of Immunology 190(5), pp. 2049-2057. (10.4049/jimmunol.1201751)
- Killick, R., Hughes, T. R., Morgan, B. P. and Lovestone, S. 2013. Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH. Neuroscience Letters 533, pp. 96-99. (10.1016/j.neulet.2012.11.008)
- Kandasamy, M. et al. 2013. Complement mediated signaling on pulmonary CD103+ dendritic cells is critical for their migratory function in response to influenza infection. PLoS Pathogens 9(1), article number: e1003115. (10.1371/journal.ppat.1003115)
- Adriani, K. S. et al. 2013. Common polymorphisms in the complement system and susceptiblity to bacterial meningitis. Journal of Infection 66(3), pp. 255-262. (10.1016/j.jinf.2012.10.008)
2012
- Paixao Cavalcante, D. et al. 2012. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney International 82(10), pp. 1084-1092. (10.1038/ki.2012.250)
- Harris, C. L., Heurich, M., Rodriguez de Cordoba, S. and Morgan, B. P. 2012. The complotype: dictating risk for inflammation and infection. Trends in Immunology 33(10), pp. 513-521. (10.1016/j.it.2012.06.001)
- Ingram, G. et al. 2012. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Multiple Sclerosis Journal 18(10), pp. 1401-1411. (10.1177/1352458512438238)
- Kempshall, E., Thebault, S., Morgan, B. P., Harris, C. L. and Gallimore, A. M. 2012. Complement-induced protection: an explanation for the limitations of cell-based tumour immunotherapies. Immunology and Cell Biology 90(9), pp. 869-871. (10.1038/icb.2012.30)
- Mizuno, M., Ito, Y. and Morgan, B. P. 2012. Exploiting the nephrotoxic effects of venom from the sea anemone, phyllodiscus semoni, to create a hemolytic uremic syndrome model in the rat. Marine Drugs 10(7), pp. 1582-1604. (10.3390/md10071582)
- Elvington, M., Huang, Y., Morgan, B. P., Qiao, F., van Rooijen, N., Atkinson, C. and Tomlinson, S. 2012. A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood 119(25), pp. 6043-6051. (10.1182/blood-2011-10-383232)
- Mizuno, M. et al. 2012. Membrane complement regulators protect against fibrin exudation increases in a severe peritoneal inflammation model in rats. American Journal of Physiology-Renal Physiology 302(10), pp. F1245-F1251. (10.1152/ajprenal.00652.2011)
- Sacks, S. and Morgan, B. P. 2012. Complement UK - how and why it started [Editorial]. Immunobiology 217(2), pp. 125-126. (10.1016/j.imbio.2011.05.001)
- Pappworth, I. Y., Hayes, C., Dimmick, J., Morgan, B. P., Holers, V. M. and Marchbank, K. J. 2012. Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression. Immunobiology 217(2), pp. 147-157. (10.1016/j.imbio.2011.06.001)
- Ramaglia, V. et al. 2012. C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proceedings of the National Academy of Sciences 109(3), pp. 965-970. (10.1073/pnas.1111924109)
- Gibson, J. et al. 2012. Variation in complement component C1 inhibitor in age-related macular degeneration. Immunobiology 217(2), pp. 251-255. (10.1016/j.imbio.2011.07.015)
- Thomas, A. D., Orren, A., Connaughton, J., Feighery, C., Morgan, B. P. and Roberts, A. G. 2012. Characterization of a large genomic deletion in four Irish families with C7 deficiency. Molecular Immunology 50(1-2), pp. 57-59. (10.1016/j.molimm.2011.12.002)
2011
- Ingram, G., Hakobyan, S., Loveless, S., Robertson, N. and Morgan, B. P. 2011. Complement regulator factor H in multiple sclerosis. Journal of Cellular Biochemistry 112(10), pp. 2653-2654. (10.1002/jcb.23204)
- Paringe, V., Bloom, A. C., Choy, E. H. S., Morgan, B. P. and Williams, A. S. 2011. Compromised expression of the complement membrane inhibitor CD59a propagates age-related joint degeneration in mice [Poster Abstract]. Arthritis and Rheumatism 63(s10), pp. S947-S947. (10.1002/art.33310)
- Bloom, A. C., Collins, F., Evans, B. A. J., Aeschlimann, D. P., Morgan, B. P. and Williams, A. S. 2011. CD59 an unexpected protective role in bone [Abstract]. Bone 48, pp. S161-S162.
- de Córdoba, S. R., Harris, C. L., Morgan, B. P. and Llorca, O. 2011. Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway. Biochimica et Biophysica Acta - Molecular Basis of Disease 1812(1), pp. 12-22. (10.1016/j.bbadis.2010.09.002)
- Morgan, B. P. 2011. Therapeutic Agents for Hereditary Angioedema [Letter]. New England Journal of Medicine 364(1), pp. 86.
- Raby, A. et al. 2011. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. European Journal of Immunology 41(9), pp. 2741-2752. (10.1002/eji.201041350)
- Lewis, R. D., Perry, M. J., Guschina, I., Jackson, C. L., Morgan, B. P. and Hughes, T. R. 2011. CD55 deficiency protects against atherosclerosis in ApoE-deficient mice via C3a modulation of lipid metabolism. American Journal of Pathology 179(4), pp. 1601-1607. (10.1016/j.ajpath.2011.06.015)
- Heurich, M., Martinez-Barricarte, R., Francis, N., Roberts, D. L., Rodriguez de Cordoba, S., Morgan, B. P. and Harris, C. L. 2011. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proceedings of the National Academy of Sciences of the United States of America 108(21), pp. 8761-8766. (10.1073/pnas.1019338108)
- Roversi, P. et al. 2011. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proceedings of the National Academy of Sciences of the United States of America 108(31), pp. 12839-12844. (10.1073/pnas.1102167108)
- Bubeck, D., Roversi, P., Donev, R. M., Morgan, B. P., Llorca, O. and Lea, S. M. 2011. Structure of human complement C8, a precursor to membrane attack. Journal of Molecular Biology 405(2), pp. 325-330. (10.1016/j.jmb.2010.10.031)
- Heurich, B. et al. 2011. Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. Journal of Neuroimmunology 235(1-2), pp. 104-109. (10.1016/j.jneuroim.2011.03.011)
- Woehrl, B. et al. 2011. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. Journal of Clinical Investigation 121(10), pp. 3943-3953. (10.1172/JCI57522)
- Roversi, P. et al. 2011. Structures of the rat complement regulator CrrY. Acta Crystallographica Section F: Structural Biology and Crystallization Communications 67(7), pp. 739-743. (10.1107/S1744309111016551)
- Lueck, K. et al. 2011. Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration. Eye 25(8), pp. 1074-1082. (10.1038/eye.2011.109)
2010
- Martínez-Barricarte, R. et al. 2010. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation 120(10), pp. 3702-3712. (10.1172/JCI43343)
- Ingram, G. et al. 2010. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133(6), pp. 1602-1611. (10.1093/brain/awq085)
- Manickam, B., Jha, P., Hepburn, N. J., Morgan, B. P., Harris, C. L., Bora, P. S. and Bora, N. S. 2010. Suppression of complement activation by recombinant Crry inhibits experimental autoimmune anterior uveitis (EAAU). Molecular Immunology 48(1-3), pp. 231-239. (10.1016/j.molimm.2010.08.006)
- Tediose, T., Kolev, M. V., Baalasubramanian, S., Brennan, P., Morgan, B. P. and Donev, R. M. 2010. Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation [RETRACTED]. Nucleic Acids Research 38(9), pp. 2799-2812. (10.1093/nar/gkq013)
- Morgan, B. P. 2010. Hereditary Angioedema - Therapies Old and New [Editorial]. New England Journal of Medicine 363(6), pp. 581-583. (10.1056/NEJMe1006450)
- Clark, S. J., Perveen, R., Hakobyan, S., Morgan, B. P., Sim, R. B., Bishop, P. N. and Day, A. J. 2010. Impaired Binding of the Age-related Macular Degeneration-associated Complement Factor H 402H Allotype to Bruch's Membrane in Human Retina. Journal of Biological Chemistry 285(39), pp. 30192-30202. (10.1074/jbc.M110.103986)
- Bora, N. S. et al. 2010. Recombinant Membrane-targeted Form of CD59 Inhibits the Growth of Choroidal Neovascular Complex in Mice. Journal of Biological Chemistry 285(44), pp. 33826-33833. (10.1074/jbc.M110.153130)
- Lewis, R. D., Jackson, C. L., Morgan, B. P. and Hughes, T. R. 2010. The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice. Molecular Immunology 47(5), pp. 1098-1105. (10.1016/j.molimm.2009.10.035)
- Johnson, S. A. et al. 2010. Impact of compound heterozygous complement factor H mutations on development of atypical hemolytic uremic syndrome - A pedigree revisited. Molecular Immunology 47(7-8), pp. 1585-1591. (10.1016/j.molimm.2009.12.001)
- Ingram, G., Hakobyan, S., Robertson, N. and Morgan, B. P. 2010. Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. Journal of Neuroimmunology 223(1-2), pp. 124-127. (10.1016/j.jneuroim.2010.03.014)
- Copland, D. A. et al. 2010. Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis. Clinical and Experimental Immunology 159(3), pp. 303-314. (10.1111/j.1365-2249.2009.04070.x)
- Mizuno, T. et al. 2010. Specific collaboration between rat membrane complement regulators Crry and CD59 protects peritoneum from damage by autologous complement activation. Nephrology Dialysis Transplantation 26(6), pp. 1821-1830. (10.1093/ndt/gfq683)
- Harhausen, D., Khojasteh, U., Stahel, P. F., Morgan, B. P., Nietfeld, W., Dirnagl, U. and Trendelenburg, G. 2010. Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice. Journal of Neuroinflammation 7, pp. 15-26. (10.1186/1742-2094-7-15)
- Qiao, F., Atkinson, C., Kindy, M. S., Shunmugavel, A., Morgan, B. P., Song, H. and Tomlinson, S. 2010. The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury. American Journal of Pathology 177(6), pp. 3061-3070. (10.2353/ajpath.2010.100158)
- Ten, V. S. et al. 2010. Complement component C1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. Journal of Neuroscience 30(6), pp. 2077-2087. (10.1523/JNEUROSCI.5249-09.2010)
- Hakobyan, S., Tortajada, A., Harris, C. L., de Córdoba, S. R. and Morgan, B. P. 2010. Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney International 78(8), pp. 782-788. (10.1038/ki.2010.275)
2009
- Ramaglia, V. et al. 2009. Complement inhibition accelerates regeneration in a model of peripheral nerve injury. Molecular Immunology 47(2-3), pp. 302-309. (10.1016/j.molimm.2009.09.019)
- Tortajada, A., Montes, T., Martinez-Barricarte, R., Morgan, B. P., Harris, C. L. and de Cordoba, S. R. 2009. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Human Molecular Genetics 18(18), pp. 3452-3461. (10.1093/hmg/ddp289)
- Ramaglia, V., King, R. H. M., Morgan, B. P. and Baas, F. 2009. Deficiency of the complement regulator CD59a exacerbates Wallerian degeneration. Molecular Immunology 46(8-9), pp. 1892-1896. (10.1016/j.molimm.2009.01.017)
- Hughes, T. R., Ross, K. S., Cowan, G. J. M., Baalasubramanian, S., Harris, C. L., Mitchell, T. J. and Morgan, B. P. 2009. Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59. Molecular Immunology 46(7), pp. 1561-1567. (10.1016/j.molimm.2009.01.003)
- Montes, T., Tortajada, A., Morgan, B. P., Rodriguez de Cordoba, S. and Harris, C. L. 2009. Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proceedings of the National Academy of Sciences 106(11), pp. 4366-4371. (10.1073/pnas.0812584106)
- Scola, A., Johswich, K., Morgan, B. P., Klos, A. and Monk, P. N. 2009. The human complement fragment receptor, C5L2, is a recycling decoy receptor. Molecular Immunology 46(6), pp. 1149-1162. (10.1016/j.molimm.2008.11.001)
- Ruseva, M. M. et al. 2009. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Molecular Immunology 46(5), pp. 803-811. (10.1016/j.molimm.2008.09.003)
- Kolev, M., Ruseva, M. M., Harris, C. L., Morgan, B. P. and Donev, R. M. 2009. Implication of complement system and its regulators in Alzheimer's Disease. Current Neuropharmacology 7(1), pp. 1-8.
- Baalasubramanian, S., Longhi, M. P., Gallagher, K. M. E., Betts, G. J., Morgan, B. P., Godkin, A. J. and Gallimore, A. M. 2009. CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?. The Journal of Immunology 182(9), pp. 5203-5207. (10.4049/jimmunol.0804243)
- Arnold, D. F., Roberts, A. G., Thomas, A. G., Ferry, B., Morgan, B. P. and Chapel, H. 2009. A novel mutation in a patient with a deficiency of the eighth component of complement associated with recurrent meningococcal meningitis. Journal of Clinical Immunology 29(5), pp. 691-695. (10.1007/s10875-009-9295-7)
- Kolev, M., Tediose, T., Baalasubramanian, S., Harris, C. L., Thome, J., Morgan, B. P. and Donev, R. M. 2009. Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration. The Pharmacogenomics Journal 10(1), pp. 12-19. (10.1038/tpj.2009.52)
- Ingram, G., Hakobyan, S., Robertson, N. and Morgan, B. P. 2009. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clinical and Experimental Immunology 155(2), pp. 128-139. (10.1111/j.1365-2249.2008.03830.x)
- Stahel, P. F. et al. 2009. Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice. Journal of Neuroinflammation 6, pp. 2-13. (10.1186/1742-2094-6-2)
- Savage, D. B. et al. 2009. Complement Abnormalities in Acquired Lipodystrophy Revisited. Journal of Clinical Endocrinology & Metabolism 94(1), pp. 10-16. (10.1210/jc.2008-1703)
- McColl, A., Bournazos, S., Franz, S., Perretti, M., Morgan, B. P., Haslett, C. and Dransfield, I. 2009. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. The Journal of Immunology 183(3), pp. 2167-2175. (10.4049/jimmunol.0803503)
- Mizuno, M. et al. 2009. Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model. The Journal of Immunology 183(2), pp. 1403-1412. (10.4049/jimmunol.0804245)
2008
- Hakobyan, S. et al. 2008. Complement factor H binds to denatured rather than to native pentameric C-reactive protein. Journal of Biological Chemistry 283(45), pp. 30451-30460. (10.1074/jbc.M803648200)
- Donev, R. M., Gray, L. C., Baalasubramanian, S., Hughes, T. R., Van Den Berg, C. W. and Morgan, B. P. 2008. Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma [RETRACTED]. Cancer Research 68(14), pp. 5979-5987. (10.1158/0008-5472.CAN-07-6828)
- Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111(10), pp. 5187-5194. (10.1182/blood-2007-10-117283)
- Ramaglia, V. et al. 2008. Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injury. American Journal of Pathology 172(4), pp. 1043-1052. (10.2353/ajpath.2008.070660)
- Hepburn, N. J., Ruseva, M. M., Harris, C. L. and Morgan, B. P. 2008. Complement, roles in renal disease and modulation for therapy. Clinical Nephrology 70(5), pp. 357-376.
- Donev, R. M., Baalasubramanian, S., Mizuno, M. and Morgan, B. P. 2008. The mouse complement regulator CD59b is significantly expressed only in testis and plays roles in sperm acrosome activation and motility [RETRACTED]. Molecular Immunology 45(2), pp. 534-542. (10.1016/j.molimm.2007.05.011)
- Hepburn, N. J., Chamberlain-Banoub, J. L., Williams, A. S., Morgan, B. P. and Harris, C. L. 2008. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: a model agent for long-term complement inhibition in vivo. Molecular Immunology 45(2), pp. 395-405. (10.1016/j.molimm.2007.06.144)
- Willison, H. J., Halstead, S. K., Beveridge, E., Zitman, F. M. P., Greenshields, K. N., Morgan, B. P. and Plomp, J. J. 2008. The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barré syndrome. Journal of Neuroimmunology 201, pp. 172-182. (10.1016/j.jneuroim.2008.05.028)
- Leite, M. I. et al. 2008. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 131(7), pp. 1940-1952. (10.1093/brain/awn092)
- Hakobyan, S. et al. 2008. Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration. Investigative Ophthalmology and Visual Science 49(5), pp. 1983-1990. (10.1167/iovs.07-1523)
2007
- Athisayaraj, T., Henley, P., Asderakis, A., Morgan, B. and Chavez, R. 2007. Complement activation associated to ischaemia and reperfusion in clinical renal transplantation. Molecular Immunology 44(16), pp. 3935. (10.1016/j.molimm.2007.06.065)
- Hepburn, N. J., Williams, A. S., Morgan, B. P. and Harris, C. L. 2007. In Vivo Characterization and Therapeutic Efficacy of a C5-specific Inhibitor from the Soft Tick Ornithodoros moubata. J Biol Chem 282, pp. 8292-8299. (10.1074/jbc.M609858200)
- Harris, C. L., Cordoba, S. R. d., Jorge, E. G. d. and Morgan, B. P. 2007. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proceedings of the National Academy of Sciences 104(1), pp. 240-5. (10.1073/pnas.0603420103)
- Harris, C. L., Morgan, B. P., Pettigrew, D. and Lea, S. 2007. Decay-accelerating factor must bind both components of the complement alternative pathway c3 convertase to mediate efficient decay. Journal of Immunology 178, pp. 352-359.
- Hepburn, N. J., Williams, A. S., Chamberlain, J. C., Hamer, J., Nunn, M. A., Morgan, B. P. and Harris, C. L. 2007. In vivo characterisation and therapeutic efficacy of a C5-specific inhibitor [Abstract]. Molecular Immunology 44(1-3), pp. 183-183. (10.1016/j.molimm.2006.07.087)
- Mizuno, M., Donev, R. M., Harris, C. L. and Morgan, B. P. 2007. CD55 in rat male reproductive tissue: Differential expression in testis and expression of a unique truncated isoform on spermatozoa. Molecular Immunology 44(7), pp. 1613-1622. (10.1016/j.molimm.2006.08.018)
- Sivasankar, B. et al. 2007. CD59a deficient mice display reduced B cell activity and antibody production in response to T-dependent antigens. Molecular Immunology 44(11), pp. 2978-2987. (10.1016/j.molimm.2006.12.025)
2006
- Omidvar, N., Wang, E. C. Y., Brennan, P., Longhi, M. P., Smith, R. A. G. and Morgan, B. P. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. Journal of immunology 176(5), pp. 2915-2923.
- Omidvar, N., Wang, E. C. Y., Brennan, P., Longhi, M. P., Smith, R. A. G. and Morgan, B. P. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. The Journal of Immunology 176(5), pp. 2915-2923. (10.4049/jimmunol.176.5.2915)
- Donev, R. M., Cole, D. S., Sivanaskar, B., Hughes, T. R. and Morgan, B. P. 2006. p53 regulates cellular resistance to complement lysis through enhanced expression of CD59 [RETRACTED]. Cancer Research 66(4), pp. 2451-8. (10.1158/0008-5472.CAN-05-3191)
- Donev, R. M. and Morgan, B. P. 2006. A quantitative method for comparison of expression of alternatively spliced genes using different primer pairs. Journal of Biochemical and Biophysical Methods 66(1-3), pp. 23-31. (10.1016/j.jbbm.2005.11.001)
2005
- Longhi, M. P., Baalasubramanian, S., Omidvar, N., Morgan, B. P. and Gallimore, A. M. 2005. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner. Journal of Immunology 175(11), pp. 7098-7102.
- Harris, C. L., Morgan, B. P., Lea, S. M. and Abbott, R. J. 2005. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). Journal of Biological Chemistry 280(4), pp. 2569-78. (10.1074/jbc.M410179200)
- Van Beek, J. and Morgan, B. P. 2005. The role of complement in EAE. In: Lavi, E. and Constantinescu, C. S. eds. Experimental Models of Multple Sclerosis. Dordrecht: Kluwer Academic, pp. 245-267., (10.1007/0-387-25518-4_12)
2004
- Morgan, B. P., Griffiths, M., Khanom, H., Taylor, S. M. and Neal, J. W. 2004. Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats. Clinical & Experimental Immunology 138(3), pp. 430-8. (10.1111/j.1365-2249.2004.02646.x)
- Baalasubramanian, S., Harris, C. L., Donev, R. M., Mizuno, M., Omidvar, N., Song, W. and Morgan, B. P. 2004. CD59a is the primary regulator of membrane attack complex assembly in the mouse. Journal of Immunology 173, pp. 3684-3692.
- Williams, A. S., Mizuno, M., Richards, P. J., Holt, D. S. and Morgan, B. P. 2004. Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis & Rheumatism 50(9), pp. 3035-3044. (10.1002/art.20478)
- Rushmere, N. K., Knowlden, J. M., Gee, J. M. W., Harper, M. E., Robertson, J. F. R., Morgan, B. P. and Nicholson, R. I. 2004. Analysis of the level of mRNA expression of the membrane regulators of complement, Cd59, Cd55 and Cd46, in breast, cancer. International Journal of Cancer 108(6), pp. 930-936. (10.1002/ijc.11606)
- Mead, R. J., Neal, J. W., Griffiths, M. R., Linington, C., Botto, M., Lassmann, H. and Morgan, B. P. 2004. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Laboratory Investigation 84, pp. 21-28. (10.1038/labinvest.3700015)
- Harris, C. L. and Morgan, B. 2004. The many faces of the membrane regulators of complement. In: Szebeni, J. ed. The Complement System: Novel Roles in Health and Disease. Boston: Kluwer, pp. 129-166.
- Sivasankar, B., Mizuno, M., Donev, R. M., Omidvar, N., Harris, C. L., Song, W. C. and Morgan, B. P. 2004. CD59b is expressed at low level on mouse erythrocytes and has a negligible protective role in the presence of CD59a. Molecular Immunology 41(2-3), pp. 307-308. (10.1016/j.molimm.2004.03.002)
2003
- Harris, C. L., Hughes, C. E., Williams, A. S., Goodfellow, I., Evans, D. J., Caterson, B. and Morgan, B. P. 2003. Generation of anti-complement 'prodrugs': cleavable reagents for specific delivery of complement regulators to disease sites. The Journal of Biological Chemistry 278(38), pp. 36068-36076. (10.1074/jbc.M306351200)
- Clayton, A., Harris, C. L., Morgan, B. P. and Mason, M. D. 2003. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. European Journal of Immunology 33(2), pp. 522-31. (10.1002/immu.200310028)
- Spiller, O. B., Robinson, M., O'Donnell, E., Milligan, S., Morgan, B. P., Davison, A. J. and Blackbourn, D. J. 2003. Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. Journal of Virology 77(1), pp. 592-599. (10.1128/JVI.77.1.592-599.2003)
2002
- McGreal, E. P., Ikawaki, N., Akatsu, H., Morgan, B. P. and Gasque, P. 2002. Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. Journal of Immunology 168, pp. 5222-5232.
- Hiscox, S. E., Hallett, M. B., Morgan, B. P. and Van Den Berg, C. W. 2002. GPI-anchored GFP signals Ca2+ but is homogeneously distributed on the cell surface. Biochemical and Biophysical Research Communications 293(2), pp. 714-721. (10.1016/S0006-291X(02)00280-2)
- Okosieme, O. E., Parkes, A. B., McCullough, B., Doukidis, D., Morgan, B. P., Richards, C. J. and Lazarus, J. H. 2002. Complement activation in postpartum thyroiditis. QJM: An International Journal of Medicine 95(3), pp. 173-179. (10.1093/qjmed/95.3.173)
- Mead, R. J., Singhrao, S. K., Neal, J. W., Lassmann, H. and Morgan, B. P. 2002. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. Journal of Immunology 168, pp. 458-465.
2001
- Holt, D. S., Botto, M., Bygrave, A. E., Hanna, S. M., Walport, M. J. and Morgan, B. P. 2001. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 98(2), pp. 442-9. (10.1182/blood.V98.2.442)
2000
- Gasque, P., Dean, Y. D., McGreal, E. P., VanBeek, J. and Morgan, B. P. 2000. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49(1-2), pp. 171-186. (10.1016/S0162-3109(00)80302-1)
- Labeta, M. et al. 2000. Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. Journal of Experimental Medicine 191, pp. 1807-1812. (10.1084/jem.191.10.1807)
- Orren, A. 2000. Screening for complement deficiency. In: Morgan, B. P. ed. Complement Methods and Protocols., Vol. 150. Methods in Molecular Biology Springer, pp. 139-158., (10.1385/1-59259-056-X:139)
1996
- Jones, J., Davies, E., Morgan, B. P. and Hallett, M. B. 1996. Effect of inhibitors of tyrosine kinase and phospholipase C on neutrophil response to perforin attack. Immunology 89(Supp1), pp. R187-R187.
1995
- Van Den Berg, C. W., Cinek, T., Hallett, M. B., Horejsi, V. and Morgan, B. P. 1995. Exogenous CD59 incorporated into U937 cells through its glycosyl phosphatidylinositol anchor becomes associated with signalling molecules in a time dependent manner. Biochemical Society Transactions 23(2), pp. 269S. (10.1042/bst023269s)
1994
- Taylor, K. M., Morgan, B. P. and Campbell, A. K. 1994. Altered glycosylation and selected mutation in recombinant human complement component C9: effects on haemolytic activity. Immunology 83(3), pp. 501-506.
Articles
- Zelek, W. M., Bevan, R. J., Nimo, J. M., Dewilde, M., De Strooper, B. and Morgan, B. P. 2025. Targeting novel anti‐complement drugs to the brain reduces complement activation and synapse loss, and improves cognition in a mouse model of dementia. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 20(S6) (10.1002/alz.090708)
- Zelek, W. M., Bevan, R. J., Nimmo, J., Dewilde, M., De Strooper, B. and Morgan, B. P. 2024. Brain-penetrant complement inhibition mitigates neurodegeneration in an Alzheimer's disease mouse model. Brain (10.1093/brain/awae278)
- Zelek, W. M., Bevan, R. J. and Morgan, B. P. 2024. Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia. Brain, Behavior, and Immunity 118, pp. 355-363. (10.1016/j.bbi.2024.03.017)
- Baillie, K. et al. 2024. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. Med 5(3), pp. 239-253. (10.1016/j.medj.2024.01.011)
- Kamegai, N. et al. 2023. Complement terminal pathway inhibition reduces peritoneal injuries in a rat peritonitis model. Clinical & Experimental Immunology 214(2), pp. 209-218. (10.1093/cei/uxad088)
- Karbian, N. et al. 2023. Complement-membrane regulatory proteins are absent from the nodes of Ranvier in the peripheral nervous system. Journal of Neuroinflammation 20(1), article number: 245. (10.1186/s12974-023-02920-9)
- Daskoulidou, N. et al. 2023. Complement receptor 1 is expressed on brain cells and in the human brain. Glia 71(6), pp. 1522-1535. (10.1002/glia.24355)
- Veteleanu, A. et al. 2023. Complement dysregulation and Alzheimer's disease in Down syndrome. Alzheimer's & Dementia: The Journal of the Alzheimer's Association 19(4), pp. 1383-1392. (10.1002/alz.12799)
- Siggins, M. K. et al. 2023. Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19.. Immunology 168(3), pp. 473-492. (10.1111/imm.13585)
- Stevenson-Hoare, J. et al. 2023. Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer's disease. Brain 146(2), pp. 690-699. (10.1093/brain/awac128)
- Lekova, E. et al. 2022. Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive Myasthenia Gravis patients. Frontiers in Immunology 13, article number: 968206. (10.3389/fimmu.2022.968206)
- Zelek, W. M. and Morgan, B. P. 2022. Targeting complement in neurodegeneration: challenges, risks, and strategies. Trends in Pharmacological Sciences 43(8), pp. 615-628. (10.1016/j.tips.2022.02.006)
- Carpanini, S. M. et al. 2022. Terminal complement pathway activation drives synaptic Loss in Alzheimer’s disease models. Acta Neuropathologica Communications 10, article number: 99. (10.1186/s40478-022-01404-w)
- Banda, N. K. et al. 2022. Analysis of complement gene expression, clinical associations, and biodistribution of complement proteins in the synovium of early rheumatoid arthritis patients reveals unique pathophysiologic features. Journal of Immunology 208(11), pp. 2482-2496. (10.4049/jimmunol.2101170)
- Fielding, C. A. et al. 2022. SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies. eLife 11 (10.7554/eLife.74489)
- Lewis, L. A. et al. 2022. Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement. The Journal of Infectious Diseases 225(10), pp. 1861–1864. (10.1093/infdis/jiab630)
- Gytz Olesen, H. et al. 2022. Development, characterization, and in vivo validation of a humanized C6 monoclonal antibody that Inhibits the membrane attack complex. Journal of Innate Immunity (10.1159/000524587)
- Kolka, C. M. et al. 2022. C5b-9 membrane attack complex formation and extracellular vesicle shedding in Barrett's esophagus and esophageal adenocarcinoma. Frontiers in Immunology 13, article number: 842023. (10.3389/fimmu.2022.842023)
- Scurr, M. et al. 2022. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. Immunology 165(2), pp. 250-259. (10.1111/imm.13433)
- Cooze, B. et al. 2022. The association between neurodegeneration and local complement activation in the thalamus to progressive multiple sclerosis outcome.. Brain Pathology 32, article number: e13054. (10.1111/bpa.13054)
- Westacott, L. J. et al. 2022. Complement C3 and C3aR mediate different aspects of emotional behaviours; relevance to risk for psychiatric disorder. Brain, Behavior, and Immunity 99, pp. 70-82. (10.1016/j.bbi.2021.09.005)
- Torvell, M., Carpanini, S. M., Daskoulidou, N., Byrne, R. A. J., Sims, R. and Morgan, B. P. 2021. Genetic insights into the impact of complement in Alzheimer's disease. Genes 12(12), article number: 1990. (10.3390/genes12121990)
- Chakraborty, M. et al. 2021. nSeP: immune and metabolic biomarkers for early detection of neonatal sepsis-protocol for a prospective multicohort study. BMJ Open 11(12), article number: e050100. (10.1136/bmjopen-2021-050100)
- Westacott, L. J. et al. 2021. Dissociable effects of complement C3 and C3aR on survival and morphology of adult born hippocampal neurons, pattern separation, and cognitive flexibility in male mice. Brain, Behavior, and Immunity 98, pp. 136-150. (10.1016/j.bbi.2021.08.215)
- Wong, E. et al. 2021. C3 Glomerulopathy and related disorders in children. Clinical Journal of the American Society of Nephrology 16(11), pp. 1639-1651. (10.2215/CJN.00320121)
- Byrne, R. A. J., Torvell, M., Daskoulidou, N., Fathalla, D., Kokkali, E., Carpanini, S. M. and Morgan, B. P. 2021. Novel monoclonal antibodies against mouse C1q: characterisation and development of a quantitative ELISA for mouse C1q. Molecular Neurobiology 58(9), pp. 4323-4336. (10.1007/s12035-021-02419-5)
- MacKenzie, G. et al. 2021. Research priorities for neuroimmunology: identifying the key research questions to be addressed by 2030. Wellcome Open Research 6, article number: 194. (10.12688/wellcomeopenres.16997.1)
- Mc Mahon, O. et al. 2021. The rare C9 P167S risk variant for age-related macular degeneration increases polymerization of the terminal component of the complement cascade. Human Molecular Genetics 30(13), pp. 1188-1199. (10.1093/hmg/ddab086)
- Webster, J. A. et al. 2021. Development of EndoScreen chip, a microfluidic pre-endoscopy triage test for esophageal adenocarcinoma. Cancers 13(12), article number: 2865. (10.3390/cancers13122865)
- Carpanini, S. M., Harwood, J. C., Baker, E., Torvell, M., Sims, R., Williams, J. and Morgan, B. P. 2021. The impact of complement genes on the risk of late-onset Alzheimer's disease. Genes 12(3), article number: 443. (10.3390/genes12030443)
- Morgan, B. P., Gommerman, J. L. and Ramaglia, V. 2021. An “outside-in” and “inside-out” consideration of complement in the multiple sclerosis brain: lessons from development and neurodegenerative diseases. Frontiers in Cellular Neuroscience 14, article number: 600656. (10.3389/fncel.2020.600656)
- Murrell, I. et al. 2021. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. PLoS ONE 16(1), article number: e0245382. (10.1371/journal.pone.0245382)
- Rodrigues, P. R., Picco, N., Morgan, B. P. and Ghazal, P. 2021. Sepsis target validation for repurposing and combining complement and immune checkpoint inhibition therapeutics. Expert Opinion on Drug Discovery 16(5), pp. 537-551. (10.1080/17460441.2021.1851186)
- Buckland, M. S. et al. 2020. Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report. Nature Communications 11(1), article number: 6385. (10.1038/s41467-020-19761-2)
- Zelek, W. M. and Morgan, B. P. 2020. Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species. Frontiers in Immunology 11(11), article number: 612402. (10.3389/fimmu.2020.612402)
- Bevan, R. J., Hughes, T. R., Williams, P. A., Good, M. A., Morgan, B. P. and Morgan, J. E. 2020. Retinal ganglion cell degeneration correlates with hippocampal spine loss in experimental Alzheimer's disease. Acta Neuropathologica Communications 8(1), article number: 216. (10.1186/s40478-020-01094-2)
- Zelek, W. M. et al. 2020. Cerebrospinal fluid complement system biomarkers in demyelinating disease. Multiple Sclerosis 26(14), pp. 1929-1937. (10.1177/1352458519887905)
- O'Connor, D. B. et al. 2020. Research priorities for the COVID-19 pandemic and beyond: a call to action for psychological science. British Journal of Psychology 111(4), pp. 603-629., article number: e12468. (10.1111/bjop.12468)
- Zelek, W. M. et al. 2020. Complement inhibition with the C5 blocker LFG316 in severe COVID-19. American Journal of Respiratory and Critical Care Medicine 202(9), pp. 1304-1308. (10.1164/rccm.202007-2778LE)
- Zelek, W. M., Menzies, G. E., Brancale, A., Stockinger, B. and Morgan, B. P. 2020. Characterising the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. Immunology 161(2), pp. 103-113., article number: Volume161, Issue2 October 2020 Pages 103-113. (10.1111/imm.13228)
- Shi, L. et al. 2020. Dickkopf-1 overexpression in vitro nominates candidate blood biomarkers relating to Alzheimer's disease pathology. Journal of Alzheimer's Disease 77(3), pp. 1353-1368. (10.3233/JAD-200208)
- Jackson, H. M., Foley, K. E., O'Rourke, R., Stearns, T. M., Fathalla, D., Morgan, B. P. and Howell, G. R. 2020. A novel mouse model expressing human forms for complement receptors CR1 and CR2. BMC Genetics 21(1), article number: 101. (10.1186/s12863-020-00893-9)
- van Dijk, B. J. et al. 2020. Complement C5 contributes to brain injury after subarachnoid hemorrhage. Translational Stroke Research 11, pp. 678-688. (10.1007/s12975-019-00757-0)
- Mondelli, V., Di Forti, M., Morgan, B. P., Murray, R. M., Pariante, C. M. and Dazzan, P. 2020. Baseline high levels of complement component 4 predict worse clinical outcome at 1-year follow-up in first-episode psychosis. Brain, Behavior, and Immunity 88, pp. 913-915. (10.1016/j.bbi.2020.01.014)
- Altmann, T. et al. 2020. Complement factor I deficiency: a potentially treatable cause of fulminant cerebral inflammation. Neurology, Neuroimmunology and Neuroinflammation 7(3), article number: e689. (10.1212/NXI.0000000000000689)
- Ghias, M. H., Hyde, M. J., Tomalin, L. E., Morgan, B. P., Alavi, A., Lowes, M. A. and Piguet, V. 2020. Role of the complement pathway in inflammatory skin diseases: a focus on hidradenitis suppurativa. Journal of Investigative Dermatology 140(3), pp. 531-536.e1. (10.1016/j.jid.2019.09.009)
- Westwood, S. et al. 2020. Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer's disease multimodal biomarker discovery cohort. Journal of Alzheimer's Disease 74(1), pp. 213-225. (10.3233/JAD-190434)
- Cipriani, V. et al. 2020. Increased circulating levels of Factor H-Related Protein 4 are strongly associated with age-related macular degeneration. Nature Communications 11, article number: 778. (10.1038/s41467-020-14499-3)
- Shi, L. et al. 2019. Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia 15(11), pp. 1478-1488. (10.1016/j.jalz.2019.06.4951)
- Mancuso, R. et al. 2019. CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain 142(10), pp. 3243-3264. (10.1093/brain/awz241)
- Zelek, W. M., Xie, L., Morgan, B. P. and Harris, C. L. 2019. Compendium of current complement therapeutics. Molecular Immunology 114, pp. 341-352. (10.1016/j.molimm.2019.07.030)
- Mastellos, D. C. et al. 2019. 'Stealth' corporate innovation: an emerging threat for therapeutic drug development. Nature Immunology 20(11), pp. 1409-1413. (10.1038/s41590-019-0503-1)
- Zelek, W. M., Taylor, P. R. and Morgan, B. P. 2019. Development and characterisation of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species. Immunology 157(4), pp. 283-295. (10.1111/imm.13083)
- Yang, J. et al. 2019. Complement factor C5 inhibition reduces type 2 responses without affecting group 2 innate lymphoid cells in a house dust mite induced murine asthma model. Respiratory Research 20(1), pp. -., article number: 165. (10.1186/s12931-019-1136-5)
- Baker, E. et al. 2019. Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer’s disease. PLoS ONE 14(7), article number: e0218111. (10.1371/journal.pone.0218111)
- Morgan, A. R. et al. 2019. Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's & Dementia 15(6), pp. 776-787. (10.1016/j.jalz.2019.03.007)
- Zelek, W. M. et al. 2019. Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. Multiple Sclerosis 25(4), pp. 523-531. (10.1177/1352458518758927)
- Goutaudier, V. et al. 2019. C5b9 deposition in glomerular capillaries is associated with poor kidney allograft survival in antibody-mediated rejection. Frontiers in Immunology 10, pp. -., article number: 235. (10.3389/fimmu.2019.00235)
- Carpanini, S. M., Torvell, M. and Morgan, B. P. 2019. Therapeutic inhibition of the complement system in diseases of the central nervous system. Frontiers in Immunology 10, pp. -., article number: 362. (10.3389/fimmu.2019.00362)
- Kopczynska, M. et al. 2019. Complement system biomarkers in first episode psychosis. Schizophrenia Research 204, pp. 16-22. (10.1016/j.schres.2017.12.012)
- Karbian, N. et al. 2018. Molecular pathogenesis of human CD59 deficiency. Neurology Genetics 4(6), article number: e280. (10.1212/NXG.0000000000000280)
- Menny, A. et al. 2018. CryoEM reveals how the complement membrane attack complex ruptures lipid bilayers. Nature Communications 9, article number: 5316. (10.1038/s41467-018-07653-5)
- Zelek, W. M., Harris, C. L. and Morgan, B. P. 2018. Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers. Immunobiology 223(12), pp. 744-749. (10.1016/j.imbio.2018.07.016)
- Griffiths, M. R., Botto, M., Morgan, B. P., Neal, J. W. and Gasque, P. 2018. CD93 regulates central nervous system inflammation in two mouse models of autoimmune encephalomyelitis. Immunology 155(3), pp. 346-355. (10.1111/imm.12974)
- Zelek, W. M., Stott, M., Walters, D., Harris, C. L. and Morgan, B. P. 2018. Characterising a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. Immunology 155(3), pp. 396-403. (10.1111/imm.12982)
- Kopczynska, M. et al. 2018. Complement system biomarkers in epilepsy. Seizure - European Journal of Epilepsy 60, pp. 1-7. (10.1016/j.seizure.2018.05.016)
- Loveless, S. et al. 2018. Tissue microarray methodology identifies complement pathway activation and dysregulation in progressive multiple sclerosis. Brain Pathology 28(4), pp. 507-520. (10.1111/bpa.12546)
- Michailidou, I. et al. 2018. Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications 6(1), article number: 36. (10.1186/s40478-018-0536-y)
- Mihai, S. et al. 2018. Specific inhibition of complement activation significantly ameliorates autoimmune blistering disease in mice. Frontiers in Immunology 9, article number: 535. (10.3389/fimmu.2018.00535)
- Morgan, B. P. 2018. Complement in the pathogenesis of Alzheimer's disease. Seminars in Immunopathology 40(1), pp. 113-124. (10.1007/s00281-017-0662-9)
- Boshra, H., Zelek, W. M., Hughes, T. R., Rodriguez de Cordoba, S. and Morgan, B. P. 2018. Absence of CD59 in guinea pigs: Analysis of the Cavia porcellus genome suggests the evolution of a CD59 pseudogene. Journal of Immunology 200(1), pp. 327-335. (10.4049/jimmunol.1701238)
- Morgan, A., O'Hagan, C., Touchard, S., Lovestone, S. and Morgan, B. P. 2017. Effects of freezer storage time on levels of complement biomarkers. BMC Research Notes 10(1), article number: 559. (10.1186/s13104-017-2885-1)
- Stott, M., van den Berg, C., Forton, J., Monk, P., Morgan, B. P. and McGreal, E. 2017. Post-translational modification of complement anaphylatoxins during chronic neutrophilic inflammation. Molecular Immunology 89, pp. 167., article number: 103. (10.1016/j.molimm.2017.06.141)
- Taylor, R. P. et al. 2017. Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9. Clinical Immunology 181, pp. 24-28. (10.1016/j.clim.2017.05.016)
- Morgan, B. P., Boyd, C. and Bubeck, D. 2017. Molecular cell biology of complement membrane attack. Seminars in Cell and Developmental Biology
- Hakobyan, S., Luppe, S., Evans, D. R. S., Harding, K., Loveless, S., Robertson, N. P. and Morgan, B. P. 2017. Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal 23(7), pp. 946-955., article number: 135245851666900. (10.1177/1352458516669002)
- Granados-Durán, P. et al. 2017. Microbial neuraminidase induces a moderate and transient myelin vacuolation independent of complement system activation. Frontiers in Neurology 8, article number: 78. (10.3389/fneur.2017.00078)
- Morgan, A. et al. 2017. The correlation between inflammatory biomarkers and polygenic risk score in Alzheimer's Disease. Journal of Alzheimer's Disease 56(1), pp. 25-36. (10.3233/JAD-160889)
- Stover, C. M. et al. 2017. High levels of soluble C5b-9 complex in dialysis fluid may predict poor prognosis in peritonitis in peritoneal dialysis patients. PLoS ONE 12(1), article number: e0169111. (10.1371/journal.pone.0169111)
- Granados-Duran, P. et al. 2016. Complement system activation contributes to the ependymal damage induced by microbial neuraminidase. Journal of Neuroinflammation 13(115) (10.1186/s12974-016-0576-9)
- Morgan, B. P., Walters, D., Serna, M. and Bubeck, D. 2016. Terminal complexes of the complement system: new structural insights and their relevance to function. Immunological Reviews 274(1), pp. 141-151. (10.1111/imr.12461)
- Hakobyan, S. et al. 2016. Complement biomarkers as predictors of disease progression in Alzheimer's disease. Journal of Alzheimer's Disease 54(2), pp. 707-716. (10.3233/JAD-160420)
- Heurich-Sevcenco, M., Preston, R., O'Donnell, V. B., Morgan, B. P. and Collins, P. W. 2016. Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research 145, pp. 84-92. (10.1016/j.thromres.2016.07.017)
- Towner, L. D., Wheat, R. A., Hughes, T. R. and Morgan, B. P. 2016. Complement membrane attack and tumorigenesis: a systems biology approach. Journal of Biological Chemistry 291(29), pp. 14927-14938. (10.1074/jbc.M115.708446)
- Challis, R. C. et al. 2016. A de novo deletion in the regulators of complement activation cluster producing a hybrid complement factor H/complement factor H-related 3 gene in atypical hemolytic uremic syndrome. Journal of the American Society of Nephrology 27(6), pp. 1617-1624. (10.1681/ASN.2015010100)
- Watkins, L. M. et al. 2016. Complement is activated in progressive multiple sclerosis cortical grey matter lesions. Journal of Neuroinflammation 13, article number: 161. (10.1186/s12974-016-0611-x)
- Morgan, B. P. 2016. The membrane attack complex as an inflammatory trigger. Immunobiology 221(6), pp. 747-751. (10.1016/j.imbio.2015.04.006)
- Williams, P. A. et al. 2016. Inhibition of the classical pathway of the complement cascade prevents early dendritic and synaptic degeneration in glaucoma. Molecular Neurodegeneration 11, article number: 26. (10.1186/s13024-016-0091-6)
- Bloom, A. C. et al. 2016. Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice. Bone 84, pp. 253-261. (10.1016/j.bone.2015.12.014)
- Bahia El Idrissi, N., Hakobyan, S., Ramaglia, V., Geluk, A., Morgan, B. . P., Das, P. K. and Baas, F. 2016. Complement activation in leprosy: a retrospective study shows elevated circulating terminal complement complex in reactional leprosy. Clinical and Experimental Immunology 184(3), pp. 338. (10.1111/cei.12767)
- Moore, G. R. W., Laule, C., Leung, E., Pavlova, V., Morgan, B. P. and Esiri, M. M. 2016. Complement and humoral adaptive immunity in the human choroid plexus: roles for stromal concretions, basement membranes, and epithelium. Journal of Neuropathology and Experimental Neurology 75(5), pp. 415-428. (10.1093/jnen/nlw017)
- Szarvas, N. et al. 2016. Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Molecular Immunology 71, pp. 10-22. (10.1016/j.molimm.2016.01.003)
- Serna, M., Giles, J. L., Morgan, B. P. and Bubeck, D. 2016. Structural basis of complement membrane attack complex formation. Nature Communications 7, article number: 10587. (10.1038/ncomms10587)
- Triantafilou, M., Hughes, T., Morgan, B. and Triantafilou, K. 2016. Complementing the inflammasome. Immunology 147(2), pp. 152-164. (10.1111/imm.12556)
- Ruseva, M. M., Ramaglia, V., Morgan, B. P. and Harris, C. L. 2015. An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice. Proceedings of the National Academy of Sciences 112(46), pp. 14319-14324. (10.1073/pnas.1513698112)
- Mook-Kanamori, B. B. et al. 2015. Thrombin-activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis. Journal of Thrombosis and Haemostatis 13(11), pp. 2076-2086. (10.1111/jth.13132)
- Morgan, B. 2015. The role of complement in neurological and neuropsychiatric diseases. Expert Review of Clinical Immunology 11(10), pp. 1109-1119. (10.1586/1744666X.2015.1074039)
- Martínez-Barricarte, R. et al. 2015. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Molecular Immunology 66(2), pp. 263-273. (10.1016/j.molimm.2015.03.248)
- Kasanmoentalib, E. S., Valls Seron, M., Morgan, B. P., Brouwer, M. C. and van de Beek, D. 2015. Adjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial. Journal of Neuroinflammation 12(1), article number: 149. (10.1186/s12974-015-0372-y)
- Giles, J. L., Choy, E., van den Berg, C., Morgan, B. P. and Harris, C. L. 2015. Response to comment on 'Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis'. Journal of Immunology 195(1), pp. 4-4. (10.4049/jimmunol.1500968)
- Bahia El Idrissi, N. et al. 2015. M. leprae components induce nerve damage by complement activation: identification of lipoarabinomannan as the dominant complement activator. Acta Neuropathologica 129(5), pp. 653-667. (10.1007/s00401-015-1404-5)
- Ramaglia, V., Jackson, S. J., Hughes, T., Neal, J., Baker, D. and Morgan, B. 2015. Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Clinical & Experimental Immunology 180(3), pp. 432-441. (10.1111/cei.12595)
- Owen, E. P. et al. 2015. A complement C5 gene mutation, c.754G>A:p.A252T, is common in the Western Cape, South Africa and found to be homozygous in seven percent of Black African meningococcal disease cases. Molecular Immunology 64(1), pp. 170-176. (10.1016/j.molimm.2014.11.010)
- Giles, J., Choy, E. H. S., Van Den Berg, C., Morgan, B. P. and Harris, C. L. 2015. Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis. The Journal of Immunology 194(7), pp. 3029-3034. (10.4049/jimmunol.1402956)
- Subias, M. et al. 2014. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models. The Journal of Immunology 193(11), pp. 5567-5575. (10.4049/jimmunol.1402013)
- Giles, J. L., Choy, E., van den Berg, C., Morgan, B. P. and Harris, C. L. 2014. Functional analysis of a complement polymorphism (rs17611) associated with Rheumatoid Arthritis. Immunology 143(s2), pp. 181-182. (10.1111/imm.12407)
- Clark, S. J., Schmidt, C. Q., White, A. W., Hakobyan, S., Morgan, B. and Bishop, P. N. 2014. Identification of factor H-like protein 1 as the predominant complement regulator in Bruch's membrane: implications for age-related macular degeneration. The Journal of Immunology 193(10), pp. 4962-4970. (10.4049/jimmunol.1401613)
- Paixao-Cavalcante, D. et al. 2014. A humanized antibody that regulates the alternative pathway convertase: potential for therapy of renal disease associated with nephritic factors. The Journal of Immunology 192(10), pp. 4844-4851. (10.4049/jimmunol.1303131)
- Ingram, G. et al. 2014. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. Acta Neuropathologica Communications 2, article number: 53. (10.1186/2051-5960-2-53)
- Fluiter, K., Opperhuizen, A. L., Morgan, B., Baas, F. and Ramaglia, V. 2014. Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice. The Journal of Immunology 192(5), pp. 2339-2348. (10.4049/jimmunol.1302793)
- Pickering, M. C. et al. 2013. C3 glomerulopathy: consensus report. Kidney International 84(6), pp. 1079-1089. (10.1038/ki.2013.377)
- Liu, J. et al. 2013. Myeloid cells expressing VEGF and Arginase-1 following uptake of damaged retinal pigment epithelium suggests potential mechanism that drives the onset of choroidal angiogenesis in mice. PLoS ONE 8(8), article number: e72935. (10.1371/journal.pone.0072935)
- Khandhadia, S. et al. 2013. Age-related macular degeneration and modification of systemic complement factor H production through liver transplantation. Ophthalmology 120(8), pp. 1612-1618. (10.1016/j.ophtha.2013.01.004)
- Triantafilou, K., Hughes, T. R., Triantafilou, M. and Morgan, B. P. 2013. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. Journal of Cell Science 126(13), pp. 2903-2913. (10.1242/jcs.124388)
- Laudisi, F. et al. 2013. Cutting edge: The NLRP3 inflammasome links complement-mediated inflammation and IL-1β release. The Journal of Immunology 191(3), pp. 1006-1010. (10.4049/jimmunol.1300489)
- Killick, R., Hughes, T. R., Morgan, B. P. and Lovestone, S. 2013. Corrigendum to “Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH” [Neurosci. Lett. 533 (2013) 96–99] [Corrigendum]. Neuroscience Letters 545, pp. 144-144. (10.1016/j.neulet.2013.05.004)
- Goicoechea de Jorge, E. et al. 2013. Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proceedings of the National Academy of Sciences of the United States of America 110(12), pp. 4685-4690. (10.1073/pnas.1219260110)
- Clark, S. J. et al. 2013. Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. The Journal of Immunology 190(5), pp. 2049-2057. (10.4049/jimmunol.1201751)
- Killick, R., Hughes, T. R., Morgan, B. P. and Lovestone, S. 2013. Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH. Neuroscience Letters 533, pp. 96-99. (10.1016/j.neulet.2012.11.008)
- Kandasamy, M. et al. 2013. Complement mediated signaling on pulmonary CD103+ dendritic cells is critical for their migratory function in response to influenza infection. PLoS Pathogens 9(1), article number: e1003115. (10.1371/journal.ppat.1003115)
- Adriani, K. S. et al. 2013. Common polymorphisms in the complement system and susceptiblity to bacterial meningitis. Journal of Infection 66(3), pp. 255-262. (10.1016/j.jinf.2012.10.008)
- Paixao Cavalcante, D. et al. 2012. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney International 82(10), pp. 1084-1092. (10.1038/ki.2012.250)
- Harris, C. L., Heurich, M., Rodriguez de Cordoba, S. and Morgan, B. P. 2012. The complotype: dictating risk for inflammation and infection. Trends in Immunology 33(10), pp. 513-521. (10.1016/j.it.2012.06.001)
- Ingram, G. et al. 2012. Systemic complement profiling in multiple sclerosis as a biomarker of disease state. Multiple Sclerosis Journal 18(10), pp. 1401-1411. (10.1177/1352458512438238)
- Kempshall, E., Thebault, S., Morgan, B. P., Harris, C. L. and Gallimore, A. M. 2012. Complement-induced protection: an explanation for the limitations of cell-based tumour immunotherapies. Immunology and Cell Biology 90(9), pp. 869-871. (10.1038/icb.2012.30)
- Mizuno, M., Ito, Y. and Morgan, B. P. 2012. Exploiting the nephrotoxic effects of venom from the sea anemone, phyllodiscus semoni, to create a hemolytic uremic syndrome model in the rat. Marine Drugs 10(7), pp. 1582-1604. (10.3390/md10071582)
- Elvington, M., Huang, Y., Morgan, B. P., Qiao, F., van Rooijen, N., Atkinson, C. and Tomlinson, S. 2012. A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood 119(25), pp. 6043-6051. (10.1182/blood-2011-10-383232)
- Mizuno, M. et al. 2012. Membrane complement regulators protect against fibrin exudation increases in a severe peritoneal inflammation model in rats. American Journal of Physiology-Renal Physiology 302(10), pp. F1245-F1251. (10.1152/ajprenal.00652.2011)
- Sacks, S. and Morgan, B. P. 2012. Complement UK - how and why it started [Editorial]. Immunobiology 217(2), pp. 125-126. (10.1016/j.imbio.2011.05.001)
- Pappworth, I. Y., Hayes, C., Dimmick, J., Morgan, B. P., Holers, V. M. and Marchbank, K. J. 2012. Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression. Immunobiology 217(2), pp. 147-157. (10.1016/j.imbio.2011.06.001)
- Ramaglia, V. et al. 2012. C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proceedings of the National Academy of Sciences 109(3), pp. 965-970. (10.1073/pnas.1111924109)
- Gibson, J. et al. 2012. Variation in complement component C1 inhibitor in age-related macular degeneration. Immunobiology 217(2), pp. 251-255. (10.1016/j.imbio.2011.07.015)
- Thomas, A. D., Orren, A., Connaughton, J., Feighery, C., Morgan, B. P. and Roberts, A. G. 2012. Characterization of a large genomic deletion in four Irish families with C7 deficiency. Molecular Immunology 50(1-2), pp. 57-59. (10.1016/j.molimm.2011.12.002)
- Ingram, G., Hakobyan, S., Loveless, S., Robertson, N. and Morgan, B. P. 2011. Complement regulator factor H in multiple sclerosis. Journal of Cellular Biochemistry 112(10), pp. 2653-2654. (10.1002/jcb.23204)
- Paringe, V., Bloom, A. C., Choy, E. H. S., Morgan, B. P. and Williams, A. S. 2011. Compromised expression of the complement membrane inhibitor CD59a propagates age-related joint degeneration in mice [Poster Abstract]. Arthritis and Rheumatism 63(s10), pp. S947-S947. (10.1002/art.33310)
- Bloom, A. C., Collins, F., Evans, B. A. J., Aeschlimann, D. P., Morgan, B. P. and Williams, A. S. 2011. CD59 an unexpected protective role in bone [Abstract]. Bone 48, pp. S161-S162.
- de Córdoba, S. R., Harris, C. L., Morgan, B. P. and Llorca, O. 2011. Lessons from functional and structural analyses of disease-associated genetic variants in the complement alternative pathway. Biochimica et Biophysica Acta - Molecular Basis of Disease 1812(1), pp. 12-22. (10.1016/j.bbadis.2010.09.002)
- Morgan, B. P. 2011. Therapeutic Agents for Hereditary Angioedema [Letter]. New England Journal of Medicine 364(1), pp. 86.
- Raby, A. et al. 2011. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2. European Journal of Immunology 41(9), pp. 2741-2752. (10.1002/eji.201041350)
- Lewis, R. D., Perry, M. J., Guschina, I., Jackson, C. L., Morgan, B. P. and Hughes, T. R. 2011. CD55 deficiency protects against atherosclerosis in ApoE-deficient mice via C3a modulation of lipid metabolism. American Journal of Pathology 179(4), pp. 1601-1607. (10.1016/j.ajpath.2011.06.015)
- Heurich, M., Martinez-Barricarte, R., Francis, N., Roberts, D. L., Rodriguez de Cordoba, S., Morgan, B. P. and Harris, C. L. 2011. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proceedings of the National Academy of Sciences of the United States of America 108(21), pp. 8761-8766. (10.1073/pnas.1019338108)
- Roversi, P. et al. 2011. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proceedings of the National Academy of Sciences of the United States of America 108(31), pp. 12839-12844. (10.1073/pnas.1102167108)
- Bubeck, D., Roversi, P., Donev, R. M., Morgan, B. P., Llorca, O. and Lea, S. M. 2011. Structure of human complement C8, a precursor to membrane attack. Journal of Molecular Biology 405(2), pp. 325-330. (10.1016/j.jmb.2010.10.031)
- Heurich, B. et al. 2011. Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. Journal of Neuroimmunology 235(1-2), pp. 104-109. (10.1016/j.jneuroim.2011.03.011)
- Woehrl, B. et al. 2011. Complement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis. Journal of Clinical Investigation 121(10), pp. 3943-3953. (10.1172/JCI57522)
- Roversi, P. et al. 2011. Structures of the rat complement regulator CrrY. Acta Crystallographica Section F: Structural Biology and Crystallization Communications 67(7), pp. 739-743. (10.1107/S1744309111016551)
- Lueck, K. et al. 2011. Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration. Eye 25(8), pp. 1074-1082. (10.1038/eye.2011.109)
- Martínez-Barricarte, R. et al. 2010. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. Journal of Clinical Investigation 120(10), pp. 3702-3712. (10.1172/JCI43343)
- Ingram, G. et al. 2010. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133(6), pp. 1602-1611. (10.1093/brain/awq085)
- Manickam, B., Jha, P., Hepburn, N. J., Morgan, B. P., Harris, C. L., Bora, P. S. and Bora, N. S. 2010. Suppression of complement activation by recombinant Crry inhibits experimental autoimmune anterior uveitis (EAAU). Molecular Immunology 48(1-3), pp. 231-239. (10.1016/j.molimm.2010.08.006)
- Tediose, T., Kolev, M. V., Baalasubramanian, S., Brennan, P., Morgan, B. P. and Donev, R. M. 2010. Interplay between REST and nucleolin transcription factors: a key mechanism in the overexpression of genes upon increased phosphorylation [RETRACTED]. Nucleic Acids Research 38(9), pp. 2799-2812. (10.1093/nar/gkq013)
- Morgan, B. P. 2010. Hereditary Angioedema - Therapies Old and New [Editorial]. New England Journal of Medicine 363(6), pp. 581-583. (10.1056/NEJMe1006450)
- Clark, S. J., Perveen, R., Hakobyan, S., Morgan, B. P., Sim, R. B., Bishop, P. N. and Day, A. J. 2010. Impaired Binding of the Age-related Macular Degeneration-associated Complement Factor H 402H Allotype to Bruch's Membrane in Human Retina. Journal of Biological Chemistry 285(39), pp. 30192-30202. (10.1074/jbc.M110.103986)
- Bora, N. S. et al. 2010. Recombinant Membrane-targeted Form of CD59 Inhibits the Growth of Choroidal Neovascular Complex in Mice. Journal of Biological Chemistry 285(44), pp. 33826-33833. (10.1074/jbc.M110.153130)
- Lewis, R. D., Jackson, C. L., Morgan, B. P. and Hughes, T. R. 2010. The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice. Molecular Immunology 47(5), pp. 1098-1105. (10.1016/j.molimm.2009.10.035)
- Johnson, S. A. et al. 2010. Impact of compound heterozygous complement factor H mutations on development of atypical hemolytic uremic syndrome - A pedigree revisited. Molecular Immunology 47(7-8), pp. 1585-1591. (10.1016/j.molimm.2009.12.001)
- Ingram, G., Hakobyan, S., Robertson, N. and Morgan, B. P. 2010. Elevated plasma C4a levels in multiple sclerosis correlate with disease activity. Journal of Neuroimmunology 223(1-2), pp. 124-127. (10.1016/j.jneuroim.2010.03.014)
- Copland, D. A. et al. 2010. Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis. Clinical and Experimental Immunology 159(3), pp. 303-314. (10.1111/j.1365-2249.2009.04070.x)
- Mizuno, T. et al. 2010. Specific collaboration between rat membrane complement regulators Crry and CD59 protects peritoneum from damage by autologous complement activation. Nephrology Dialysis Transplantation 26(6), pp. 1821-1830. (10.1093/ndt/gfq683)
- Harhausen, D., Khojasteh, U., Stahel, P. F., Morgan, B. P., Nietfeld, W., Dirnagl, U. and Trendelenburg, G. 2010. Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice. Journal of Neuroinflammation 7, pp. 15-26. (10.1186/1742-2094-7-15)
- Qiao, F., Atkinson, C., Kindy, M. S., Shunmugavel, A., Morgan, B. P., Song, H. and Tomlinson, S. 2010. The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury. American Journal of Pathology 177(6), pp. 3061-3070. (10.2353/ajpath.2010.100158)
- Ten, V. S. et al. 2010. Complement component C1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. Journal of Neuroscience 30(6), pp. 2077-2087. (10.1523/JNEUROSCI.5249-09.2010)
- Hakobyan, S., Tortajada, A., Harris, C. L., de Córdoba, S. R. and Morgan, B. P. 2010. Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney International 78(8), pp. 782-788. (10.1038/ki.2010.275)
- Ramaglia, V. et al. 2009. Complement inhibition accelerates regeneration in a model of peripheral nerve injury. Molecular Immunology 47(2-3), pp. 302-309. (10.1016/j.molimm.2009.09.019)
- Tortajada, A., Montes, T., Martinez-Barricarte, R., Morgan, B. P., Harris, C. L. and de Cordoba, S. R. 2009. The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity. Human Molecular Genetics 18(18), pp. 3452-3461. (10.1093/hmg/ddp289)
- Ramaglia, V., King, R. H. M., Morgan, B. P. and Baas, F. 2009. Deficiency of the complement regulator CD59a exacerbates Wallerian degeneration. Molecular Immunology 46(8-9), pp. 1892-1896. (10.1016/j.molimm.2009.01.017)
- Hughes, T. R., Ross, K. S., Cowan, G. J. M., Baalasubramanian, S., Harris, C. L., Mitchell, T. J. and Morgan, B. P. 2009. Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59. Molecular Immunology 46(7), pp. 1561-1567. (10.1016/j.molimm.2009.01.003)
- Montes, T., Tortajada, A., Morgan, B. P., Rodriguez de Cordoba, S. and Harris, C. L. 2009. Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proceedings of the National Academy of Sciences 106(11), pp. 4366-4371. (10.1073/pnas.0812584106)
- Scola, A., Johswich, K., Morgan, B. P., Klos, A. and Monk, P. N. 2009. The human complement fragment receptor, C5L2, is a recycling decoy receptor. Molecular Immunology 46(6), pp. 1149-1162. (10.1016/j.molimm.2008.11.001)
- Ruseva, M. M. et al. 2009. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Molecular Immunology 46(5), pp. 803-811. (10.1016/j.molimm.2008.09.003)
- Kolev, M., Ruseva, M. M., Harris, C. L., Morgan, B. P. and Donev, R. M. 2009. Implication of complement system and its regulators in Alzheimer's Disease. Current Neuropharmacology 7(1), pp. 1-8.
- Baalasubramanian, S., Longhi, M. P., Gallagher, K. M. E., Betts, G. J., Morgan, B. P., Godkin, A. J. and Gallimore, A. M. 2009. CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?. The Journal of Immunology 182(9), pp. 5203-5207. (10.4049/jimmunol.0804243)
- Arnold, D. F., Roberts, A. G., Thomas, A. G., Ferry, B., Morgan, B. P. and Chapel, H. 2009. A novel mutation in a patient with a deficiency of the eighth component of complement associated with recurrent meningococcal meningitis. Journal of Clinical Immunology 29(5), pp. 691-695. (10.1007/s10875-009-9295-7)
- Kolev, M., Tediose, T., Baalasubramanian, S., Harris, C. L., Thome, J., Morgan, B. P. and Donev, R. M. 2009. Upregulating CD59: a new strategy for protection of neurons from complement-mediated degeneration. The Pharmacogenomics Journal 10(1), pp. 12-19. (10.1038/tpj.2009.52)
- Ingram, G., Hakobyan, S., Robertson, N. and Morgan, B. P. 2009. Complement in multiple sclerosis: its role in disease and potential as a biomarker. Clinical and Experimental Immunology 155(2), pp. 128-139. (10.1111/j.1365-2249.2008.03830.x)
- Stahel, P. F. et al. 2009. Absence of the complement regulatory molecule CD59a leads to exacerbated neuropathology after traumatic brain injury in mice. Journal of Neuroinflammation 6, pp. 2-13. (10.1186/1742-2094-6-2)
- Savage, D. B. et al. 2009. Complement Abnormalities in Acquired Lipodystrophy Revisited. Journal of Clinical Endocrinology & Metabolism 94(1), pp. 10-16. (10.1210/jc.2008-1703)
- McColl, A., Bournazos, S., Franz, S., Perretti, M., Morgan, B. P., Haslett, C. and Dransfield, I. 2009. Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages. The Journal of Immunology 183(3), pp. 2167-2175. (10.4049/jimmunol.0803503)
- Mizuno, M. et al. 2009. Zymosan, but not lipopolysaccharide, triggers severe and progressive peritoneal injury accompanied by complement activation in a rat peritonitis model. The Journal of Immunology 183(2), pp. 1403-1412. (10.4049/jimmunol.0804245)
- Hakobyan, S. et al. 2008. Complement factor H binds to denatured rather than to native pentameric C-reactive protein. Journal of Biological Chemistry 283(45), pp. 30451-30460. (10.1074/jbc.M803648200)
- Donev, R. M., Gray, L. C., Baalasubramanian, S., Hughes, T. R., Van Den Berg, C. W. and Morgan, B. P. 2008. Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma [RETRACTED]. Cancer Research 68(14), pp. 5979-5987. (10.1158/0008-5472.CAN-07-6828)
- Morton, J. et al. 2008. Circulating neutrophils maintain physiological blood pressure by suppressing bacteria and IFN -dependent iNOS expression in the vasculature of healthy mice. Blood 111(10), pp. 5187-5194. (10.1182/blood-2007-10-117283)
- Ramaglia, V. et al. 2008. Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injury. American Journal of Pathology 172(4), pp. 1043-1052. (10.2353/ajpath.2008.070660)
- Hepburn, N. J., Ruseva, M. M., Harris, C. L. and Morgan, B. P. 2008. Complement, roles in renal disease and modulation for therapy. Clinical Nephrology 70(5), pp. 357-376.
- Donev, R. M., Baalasubramanian, S., Mizuno, M. and Morgan, B. P. 2008. The mouse complement regulator CD59b is significantly expressed only in testis and plays roles in sperm acrosome activation and motility [RETRACTED]. Molecular Immunology 45(2), pp. 534-542. (10.1016/j.molimm.2007.05.011)
- Hepburn, N. J., Chamberlain-Banoub, J. L., Williams, A. S., Morgan, B. P. and Harris, C. L. 2008. Prevention of experimental autoimmune myasthenia gravis by rat Crry-Ig: a model agent for long-term complement inhibition in vivo. Molecular Immunology 45(2), pp. 395-405. (10.1016/j.molimm.2007.06.144)
- Willison, H. J., Halstead, S. K., Beveridge, E., Zitman, F. M. P., Greenshields, K. N., Morgan, B. P. and Plomp, J. J. 2008. The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barré syndrome. Journal of Neuroimmunology 201, pp. 172-182. (10.1016/j.jneuroim.2008.05.028)
- Leite, M. I. et al. 2008. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 131(7), pp. 1940-1952. (10.1093/brain/awn092)
- Hakobyan, S. et al. 2008. Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration. Investigative Ophthalmology and Visual Science 49(5), pp. 1983-1990. (10.1167/iovs.07-1523)
- Athisayaraj, T., Henley, P., Asderakis, A., Morgan, B. and Chavez, R. 2007. Complement activation associated to ischaemia and reperfusion in clinical renal transplantation. Molecular Immunology 44(16), pp. 3935. (10.1016/j.molimm.2007.06.065)
- Hepburn, N. J., Williams, A. S., Morgan, B. P. and Harris, C. L. 2007. In Vivo Characterization and Therapeutic Efficacy of a C5-specific Inhibitor from the Soft Tick Ornithodoros moubata. J Biol Chem 282, pp. 8292-8299. (10.1074/jbc.M609858200)
- Harris, C. L., Cordoba, S. R. d., Jorge, E. G. d. and Morgan, B. P. 2007. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proceedings of the National Academy of Sciences 104(1), pp. 240-5. (10.1073/pnas.0603420103)
- Harris, C. L., Morgan, B. P., Pettigrew, D. and Lea, S. 2007. Decay-accelerating factor must bind both components of the complement alternative pathway c3 convertase to mediate efficient decay. Journal of Immunology 178, pp. 352-359.
- Hepburn, N. J., Williams, A. S., Chamberlain, J. C., Hamer, J., Nunn, M. A., Morgan, B. P. and Harris, C. L. 2007. In vivo characterisation and therapeutic efficacy of a C5-specific inhibitor [Abstract]. Molecular Immunology 44(1-3), pp. 183-183. (10.1016/j.molimm.2006.07.087)
- Mizuno, M., Donev, R. M., Harris, C. L. and Morgan, B. P. 2007. CD55 in rat male reproductive tissue: Differential expression in testis and expression of a unique truncated isoform on spermatozoa. Molecular Immunology 44(7), pp. 1613-1622. (10.1016/j.molimm.2006.08.018)
- Sivasankar, B. et al. 2007. CD59a deficient mice display reduced B cell activity and antibody production in response to T-dependent antigens. Molecular Immunology 44(11), pp. 2978-2987. (10.1016/j.molimm.2006.12.025)
- Omidvar, N., Wang, E. C. Y., Brennan, P., Longhi, M. P., Smith, R. A. G. and Morgan, B. P. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. Journal of immunology 176(5), pp. 2915-2923.
- Omidvar, N., Wang, E. C. Y., Brennan, P., Longhi, M. P., Smith, R. A. G. and Morgan, B. P. 2006. Expression of glycosylphosphatidylinositol-anchored CD59 on target cells enhances human NK cell-mediated cytotoxicity. The Journal of Immunology 176(5), pp. 2915-2923. (10.4049/jimmunol.176.5.2915)
- Donev, R. M., Cole, D. S., Sivanaskar, B., Hughes, T. R. and Morgan, B. P. 2006. p53 regulates cellular resistance to complement lysis through enhanced expression of CD59 [RETRACTED]. Cancer Research 66(4), pp. 2451-8. (10.1158/0008-5472.CAN-05-3191)
- Donev, R. M. and Morgan, B. P. 2006. A quantitative method for comparison of expression of alternatively spliced genes using different primer pairs. Journal of Biochemical and Biophysical Methods 66(1-3), pp. 23-31. (10.1016/j.jbbm.2005.11.001)
- Longhi, M. P., Baalasubramanian, S., Omidvar, N., Morgan, B. P. and Gallimore, A. M. 2005. Cutting edge: murine CD59a modulates antiviral CD4+ T cell activity in a complement-independent manner. Journal of Immunology 175(11), pp. 7098-7102.
- Harris, C. L., Morgan, B. P., Lea, S. M. and Abbott, R. J. 2005. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55). Journal of Biological Chemistry 280(4), pp. 2569-78. (10.1074/jbc.M410179200)
- Morgan, B. P., Griffiths, M., Khanom, H., Taylor, S. M. and Neal, J. W. 2004. Blockade of the C5a receptor fails to protect against experimental autoimmune encephalomyelitis in rats. Clinical & Experimental Immunology 138(3), pp. 430-8. (10.1111/j.1365-2249.2004.02646.x)
- Baalasubramanian, S., Harris, C. L., Donev, R. M., Mizuno, M., Omidvar, N., Song, W. and Morgan, B. P. 2004. CD59a is the primary regulator of membrane attack complex assembly in the mouse. Journal of Immunology 173, pp. 3684-3692.
- Williams, A. S., Mizuno, M., Richards, P. J., Holt, D. S. and Morgan, B. P. 2004. Deletion of the gene encoding CD59a in mice increases disease severity in a murine model of rheumatoid arthritis. Arthritis & Rheumatism 50(9), pp. 3035-3044. (10.1002/art.20478)
- Rushmere, N. K., Knowlden, J. M., Gee, J. M. W., Harper, M. E., Robertson, J. F. R., Morgan, B. P. and Nicholson, R. I. 2004. Analysis of the level of mRNA expression of the membrane regulators of complement, Cd59, Cd55 and Cd46, in breast, cancer. International Journal of Cancer 108(6), pp. 930-936. (10.1002/ijc.11606)
- Mead, R. J., Neal, J. W., Griffiths, M. R., Linington, C., Botto, M., Lassmann, H. and Morgan, B. P. 2004. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Laboratory Investigation 84, pp. 21-28. (10.1038/labinvest.3700015)
- Sivasankar, B., Mizuno, M., Donev, R. M., Omidvar, N., Harris, C. L., Song, W. C. and Morgan, B. P. 2004. CD59b is expressed at low level on mouse erythrocytes and has a negligible protective role in the presence of CD59a. Molecular Immunology 41(2-3), pp. 307-308. (10.1016/j.molimm.2004.03.002)
- Harris, C. L., Hughes, C. E., Williams, A. S., Goodfellow, I., Evans, D. J., Caterson, B. and Morgan, B. P. 2003. Generation of anti-complement 'prodrugs': cleavable reagents for specific delivery of complement regulators to disease sites. The Journal of Biological Chemistry 278(38), pp. 36068-36076. (10.1074/jbc.M306351200)
- Clayton, A., Harris, C. L., Morgan, B. P. and Mason, M. D. 2003. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. European Journal of Immunology 33(2), pp. 522-31. (10.1002/immu.200310028)
- Spiller, O. B., Robinson, M., O'Donnell, E., Milligan, S., Morgan, B. P., Davison, A. J. and Blackbourn, D. J. 2003. Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. Journal of Virology 77(1), pp. 592-599. (10.1128/JVI.77.1.592-599.2003)
- McGreal, E. P., Ikawaki, N., Akatsu, H., Morgan, B. P. and Gasque, P. 2002. Human C1qRp is identical with CD93 and the mNI-11 antigen but does not bind C1q. Journal of Immunology 168, pp. 5222-5232.
- Hiscox, S. E., Hallett, M. B., Morgan, B. P. and Van Den Berg, C. W. 2002. GPI-anchored GFP signals Ca2+ but is homogeneously distributed on the cell surface. Biochemical and Biophysical Research Communications 293(2), pp. 714-721. (10.1016/S0006-291X(02)00280-2)
- Okosieme, O. E., Parkes, A. B., McCullough, B., Doukidis, D., Morgan, B. P., Richards, C. J. and Lazarus, J. H. 2002. Complement activation in postpartum thyroiditis. QJM: An International Journal of Medicine 95(3), pp. 173-179. (10.1093/qjmed/95.3.173)
- Mead, R. J., Singhrao, S. K., Neal, J. W., Lassmann, H. and Morgan, B. P. 2002. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. Journal of Immunology 168, pp. 458-465.
- Holt, D. S., Botto, M., Bygrave, A. E., Hanna, S. M., Walport, M. J. and Morgan, B. P. 2001. Targeted deletion of the CD59 gene causes spontaneous intravascular hemolysis and hemoglobinuria. Blood 98(2), pp. 442-9. (10.1182/blood.V98.2.442)
- Gasque, P., Dean, Y. D., McGreal, E. P., VanBeek, J. and Morgan, B. P. 2000. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49(1-2), pp. 171-186. (10.1016/S0162-3109(00)80302-1)
- Labeta, M. et al. 2000. Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. Journal of Experimental Medicine 191, pp. 1807-1812. (10.1084/jem.191.10.1807)
- Jones, J., Davies, E., Morgan, B. P. and Hallett, M. B. 1996. Effect of inhibitors of tyrosine kinase and phospholipase C on neutrophil response to perforin attack. Immunology 89(Supp1), pp. R187-R187.
- Van Den Berg, C. W., Cinek, T., Hallett, M. B., Horejsi, V. and Morgan, B. P. 1995. Exogenous CD59 incorporated into U937 cells through its glycosyl phosphatidylinositol anchor becomes associated with signalling molecules in a time dependent manner. Biochemical Society Transactions 23(2), pp. 269S. (10.1042/bst023269s)
- Taylor, K. M., Morgan, B. P. and Campbell, A. K. 1994. Altered glycosylation and selected mutation in recombinant human complement component C9: effects on haemolytic activity. Immunology 83(3), pp. 501-506.
Book sections
- Daskoulidou, N., Carpanini, S., Zelek, W. and Morgan, B. P. 2024. Involvement of complement in Alzheimer's Disease: From genetics through pathology to therapeutic strategies. In: Ellenbroek, B. A. et al. eds. Current Topics in Behavioral Neurosciences. Springer, Berlin, Heidelberg, pp. 1-22., (10.1007/7854_2024_524)
- Van Beek, J. and Morgan, B. P. 2005. The role of complement in EAE. In: Lavi, E. and Constantinescu, C. S. eds. Experimental Models of Multple Sclerosis. Dordrecht: Kluwer Academic, pp. 245-267., (10.1007/0-387-25518-4_12)
- Harris, C. L. and Morgan, B. 2004. The many faces of the membrane regulators of complement. In: Szebeni, J. ed. The Complement System: Novel Roles in Health and Disease. Boston: Kluwer, pp. 129-166.
- Orren, A. 2000. Screening for complement deficiency. In: Morgan, B. P. ed. Complement Methods and Protocols., Vol. 150. Methods in Molecular Biology Springer, pp. 139-158., (10.1385/1-59259-056-X:139)
Ymchwil
My research throughout my career has related to the complement system, its regulation and roles in disease. My current research focusses on roles of complement and other inflammatory pathways in disease with a particular focus on neurological disease.
Current and Recent Grants:
- Dementia Research Institute Cardiff (MRC-funded) Programme: 2017-2022. Value £1.5M. Complement in Alzheimer’s disease: from gene discovery to mechanisms and better drugs.
- Wellcome Trust Consortium for Neuroimmunology of Mood Disorders and Alzheimer’s Disease. 2015-2020. Value £5.7M (app. £0.4M to Cardiff). Lead for inflammatory biomarkers theme.
- Alzheimer’s Research UK Pilot Grant. 2015-2016. Value £49,437. “Complement
- and microglial activation in mouse models of dementia”.
- BBSRC Case Studentship with GSK; 2015-2019. Value app. £180,000. “Inflammatory effects of the complement terminal pathway: exploring the molecular mechanisms”.
- MS Society Studentship; 2012-2015; Value £104,350. Title: “Mechanisms and roles of microglial priming and activation in experimental demyelination and human MS”.
- BBSRC CASE Studentship with GSK; 2012-2016; Value: ~£150,000.Title: “Mechanisms responsible for differential bactericidal activities of human and rabbit complement against Neisseria meningitidis”.
- Fight for Sight Project Grant; 2013-2016; Value: £169,937. Title: 'The complotype as a predictor of disease and response to therapy in AMD'.
- BHF Project Grant; 2013-2016; Value; £297,000. Title: “The role of complement dysregulation and C3adesArg in atherosclerosis".
- Sponsor of 17 Research Fellows (MRC; WT; ARC); Supervised >30 PhD/ MD students.
Addysgu
Over thirty years experience of delivering lectures and tutorials on various aspects of Biochemistry and Immunology to Medical Students and Science Students.
As Dean of Medicine (2008-2013), led the introduction of a completely new integrated spiral curriculum across all five years of the MBBCh course.
Small group teaching lead and OSCE examiner for medical students.
Supervised over thirty students to successful completion of PhD, MD or MSc degrees.
Lead for the GW4CAT Clinical Academic Training Programme.
Bywgraffiad
Current position:
Professor of Immunology, Director of Systems Immunity URI, Cardiff University
Previous positions:
1980-1981: House Physician, Cardiff Hospital Group.
1981-1984: MRC Training Fellow, Medical Biochemistry, Welsh National School of Medicine.
1984-1985: MRC Travelling Fellow, Johns Hopkins Medical School, Baltimore, and University of Florida, Gainesville, Florida
1/1/86-30/9/87: Clinical Lecturer in Medical Biochemistry, University of Wales College of Medicine.
1/10/87 – 30/9/01: Wellcome Trust Senior Clinical Research Fellow and Honorary Consultant, Medical Biochemistry, Wales College of Medicine. Appointed Professor from 1/11/95.
1/10/01 – 31/3/09: Head, Department of Medical Biochemistry and Immunology, School of Medicine, Cardiff University. Honorary Consultant in Medical Biochemistry; Cardiff and Vale NHS Trust.
1/09/07 – 31/3/09: Dean of Medical Research, School of Medicine, Cardiff University.
1/04/09 – 31/12/13: Dean of Medicine and Head of School, School of Medicine, Cardiff University.
Education:
1977 B.Sc. (1st Class Hons) Medical Biochemistry.
1980 M.B., B.Ch. (University of Wales).
1984 Ph.D. (Wales) "Biochemistry and Pathology of Complement Component C9".
1988 Membership of the Royal College of Pathologists (MRCPath).
1997 Fellowship of the Royal College of Pathologists (FRCPath).
Anrhydeddau a dyfarniadau
Awards and elections:
1999 Elected to Fellowship of the Academy of Medical Sciences (FMedSci)
2000 Elected to Membership of the Royal College of Physicians (MRCP).
2001 Elected to Membership of the Association of Physicians.
2002-2007 Chair; European Complement Network
2011-2014 President; International Complement Society
2015 Elected to Fellowship of Academia Europaea.
National/International funding roles and panels:
1994-2000 Member, International Interest Group of The Wellcome Trust.
2001 – 2006 Member, MRC Clinical Training and Career Development Panel.
2004 - 2006 Member, Wellcome Trust Basic Immunology and Infection Panel.
2005-2008 Council Member, Academy of Medical Sciences.
2006-2012 Member then Chair, Wellcome Trust Clinical Fellowship Interview Panel.
2008- 2012 Member, Wellcome Trust Pathogens, Immunology & Population Health Strategy Committee
2013- 2017 Member, Biology and Medicine Panel, Research Grants Council of Hong Kong.
2011-2015 Council Member, Medical Research Council
Aelodaethau proffesiynol
Fellow of the Academy of Medical Sciences (FMedSci)
Fellow of the Royal College of Pathologists
Member of the Royal College of Physicians (MRCP).
Member of the Association of Physicians.
Fellow of the Academia Europaea.
Safleoedd academaidd blaenorol
-
01/2014- present: Professor of Immunology, Director of Systems Immunity URI, Cardiff University.
-
04/09 – 12/13: Dean of Medicine and Head of School, School of Medicine, Cardiff University.
-
09/07 – 03/09: Dean of Medical Research, School of Medicine, Cardiff University.
-
10/01 – 03/09: Head, Department of Medical Biochemistry and Immunology, School of Medicine, Cardiff University. Honorary Consultant in Medical Biochemistry; Cardiff and Vale NHS Trust.
-
10/87 – 09/01: Wellcome Trust Senior Clinical Research Fellow and Honorary Consultant, Medical Biochemistry, Wales College of Medicine. Appointed Professor from 1/11/95.
Pwyllgorau ac adolygu
Grants committees and panels:
Medical Research Council; Council Member (2011- 2015).
Chair, NISCHR Grants Funding committee; (2013- current).
Chair, Wellcome Trust Clinical Fellowship Interview Panel from December 2007-2012.
Member, Wellcome Trust Clinical Fellowship Interview Panel (2006 - 2012);
Member, Wellcome Trust Pathogens, Immunology & Population Health Strategy Committee (2008- 2012).
Member, MRC College of Experts (2005 - 2010).
Deputy Chair, Wales Office of Research and Development Funding Committee, (2004 - 2009);
Member, Wellcome Trust Basic Immunology and Infection Panel (2004 - 2006).
Member, MRC Clinical Training and Career Development Panel (2001 - 2006).
Member, International Interest Group of The Wellcome Trust (responsible for all overseas funding initiatives by The Trust) (1994-2000).
National/International bodies:
Council Member; Academy of Medical Sciences (2005-2008).
Member; UCEA Clinical Academic Staff Advisory Group (CASAG) (2009-2015).
Member; UK Healthcare Education Advisory Committee (UK HEAC) (2010-2015).
Member; Welsh Medical Committee (2009 – 2013).
Member; AcMedSci committee advising on MB PhD schemes.
Member; AcMedSci Academic Careers Committee.
Member; RAE 2008 sub-panel A3 (Infection and Immunity).
Member; NISCHR Senior Faculty (2013- ongoing).
Former Meetings Secretary, Treasurer, Trustee and Member of Council, British Society for Immunology.
UK Representative on International Complement Society Committee (2003- 2015).
Chair of European Complement Network (2001-2007).
Deputy Chair, Grants Review Committee, Wales Office of Research and Development (WORD).
Member of Scientific Strategy Committee, Tenovus Cancer Research (2000 - 2012).
Member, Biology and Medicine Panel, Research Grant Council of Hong Kong (2013-ongoing).
Contact Details
+44 29206 87096
Adeilad Henry Wellcome ar gyfer Ymchwil Biofeddygol, Ystafell 3F08, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN